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Abstract: Colorectal cancer (CRC) is the 4th most commonly detected cancer in the USA. 
Despite promising advances, the 5-year survival rate for the metastatic disease remains 
dismal (<15%) due to the presence of chemo-resistant and immune-suppressive tumor 
microenvironment. In addition, CRC outcomes can suffer from a lack of real-time 
treatment monitoring, preventing rapid treatment interventions. To overcome these 
barriers, we hypothesized that, modifying low temperature sensitive liposomes (LTSLs) 
that release the encapsulated doxorubicin at >40⁰C with ultrasound contrast agents and 
bacterial attachments can improve the real-time chemo-immunotherapy of CRC. Towards 
these goals, we investigated the following specific aims in murine models of colon 
cancer: 1) Develop echogenic-LTSL (E-LTSL) for real-time ultrasound-enhanced 
reporting of tumor temperature and doxorubicin delivery, 2) Utilize tumor homing 
Salmonella typhimurium for LTSL delivery and enhanced chemo-immunotherapy with 
High Intensity Focused Ultrasound (HIFU) tumor heating (~42°C), and 3) Investigate the 
ability of magnetic bacteria Magnetospirillim magneticum (AMB-1) to aid LTSL tumor 
drug delivery under magnetic guidance. Our data showed that intratumoral vascular 
contrast of E-LTSL as a function of temperature and doxorubicin delivery was strongly 
correlated, enabling robust estimation of temporal variation in colon tumor temperature 
and drug delivery.  LTSL attachment didn’t impact Salmonella viability and improved 
chemo-immunotherapy outcomes in murine colon cancers by promoting the population of 
M1 macrophages with HIFU heating. Finally, the use of magnetic guidance for AMB-
LTSL significantly reduced the colon cancer viability by enhancing cellular and tumor 
localizations of doxorubicin. In conclusion, we found that multifunctional LTSL 
formulations significantly improved the CRC treatment outcomes in murine models by 
aiding the real-time monitoring and removing the resistive and suppressive tumor 
microenvironment features.  
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CHAPTER I 
 
 
REVIEW OF LITERATURE 
Cancer statistics and gaps in current treatment protocols 
According to the American Cancer Society, a total of 1.7 million new cancer cases and 
609,640 cancer deaths is estimated to occur in the United States in 20181. Despite 
promising advances, cancer remains a challenging disease to treat, thereby putting 
significant burdens on the healthcare system.  Currently, surgery, radiation, and 
chemotherapy are regarded as the gold standard approaches for cancer treatment2. 
Depending on the type and stage of cancer, each of these modalities, or a combination, 
are administered to the patient, however, achieving a robust response in malignant 
diseases has been dismal. To overcome these barriers, newer treatment options such as 
gene therapy, bone marrow transplantation and targeted treatments are increasingly being 
translated in patients to improve outcomes and enhance survival 3-5. This is promising but 
cancer cells notoriously evolve, adapt and switch their survival pathways to develop 
resistance against therapeutic approaches. Most cancer treatment modalities are also often 
accompanied by severe side effects, reducing patient’s quality of life. All of these 
challenges underscore the need to enhance targeted therapy approaches such that they 
provide robust and non-toxic outcomes in cancer patients. 
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In particular, colon cancer is the 4th most commonly detected cancer in USA6. The outcomes 
in colon cancer are highly dependent on the stage of disease, and tumor 
microenvironments78. For example, early stage colorectal cancer is efficiently managed by 
surgical resection; however advanced staged disease (III and IV) typically requires 
chemotherapy with oxaliplatin, fluoropyrimidine 5-fluorocil, leucovorin, doxorubicin, or 
combinations of these drugs 9-11. Chemotherapy with such agents typically has low 
specificity, demonstrate gastrointestinal toxicities and drug resistance12-14.  The objective of 
this dissertation is to address such treatment barriers by developing novel device-directed 
approaches with nanoparticles. To do so, we focused on the aspects of localized 
chemotherapy delivery and immunotherapy with heat, magnetic field and bacteria in murine 
colon cancer model to ease clinical translation.   
Role of nanotechnology in improving chemotherapy outcomes in colon cancer patients 
Conventional chemotherapy of colon cancer can be limited by the low specificity, rapid drug 
clearance, and biodegradation of anticancer drugs15. According to Hong et al, <2% of the 
total administered drug typically reaches the tumor site16. One approach to enhance drug 
accumulation can be by targeting specific therapeutic cargo into the tumor cells. This is done 
using antibody directed enzyme pro-drug therapy, immune- and protein conjugates and nano-
sized drug carriers17-19.  Amongst these agents,  nano-sized drug carriers of various 
composition that encapsulate anti-cancer drugs has gained significant interest and testing in 
clinical trials20. Nanomedicines have high surface-to-volume ratios and favorable drug 
release profile which provides enhanced specificity21. Nanomedicines exploit the enhanced 
permeability and retention effect (EPR), characteristic of tumor tissues to boost the passive 
accumulation of chemotherapy in the tumors22,23. Further, the incorporation of targeting 
ligands for the active targeting of over-expressed targets in the cancer cell can significantly 
improve the localized bioavailability by ~2-10 fold compared to conventional medicine24,25. 
Thus, the versatility of nanomedicines has made it possible to bridge translational gaps in 
tumor imaging, targeting, drug delivery, and treatment monitoring26,27.   
In this project, we primarily focus on liposomes. Liposomes have demonstrated the greatest 
success in clinical trials28. Liposomes are biocompatible, moderately immunogenic29, 
andtunable for controlled drug release in tumors30. Liposomes also protect the drugs from 
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premature degradation in blood vessels30,31,  accumulate in tumors by the EPR effect32, and 
are capable of delivering a wide-spectrum of cargo agents33,34. A detailed description of the 
current liposomal approach and translational barriers are described below. 
Liposomes 
Liposomes are vesicular structure composed of a lipid bilayer enclosing a hydrophilic inner 
phase. They were first described by Alec Bangham in 1961 and since then have been 
extensively investigated for drug and gene delivery35. Liposomes enter a cell by endocytosis, 
adsorption, and lipid transfer. Most liposomes are composed of phospholipid or synthetic 
amphiphiles incorporated with sterols such as cholesterol. The phospholipids spontaneously 
form vesicular structures upon hydration in aqueous solutions, and thus are ideal for ferrying 
hydrophobic and hydrophilic drugs36,37. Several methods such as thin film hydration, reverse 
phase evaporation, ethanol injections, sonication, and freeze-drying have been employed for 
the synthesis of liposomes38. Properties of the liposomes particles can differ considerably 
with the lipid composition, surface charge, size and the method of preparation, resulting in 
unique therapeutics tailored to physical properties of a tumor.  
Characteristics of liposomes 
Liposomes can be unilamellar or multilamellar, and their sizes can range from  0.025µm to 
2.5 µm39. The essential physical parameter that determines the pharmacokinetics and 
pharmacodynamics of liposomes are the number of membrane layers (Table 1) and size. 
These features can influence the drug encapsulation efficiencies and release rates upon 
parenteral injections39.  Liposomes with single phospholipid bilayer are divided into two 
categories: (1) Small unilamellar vesicles with <0.1µm diameter that have low entrapped 
volume to lipid ratio and long circulation half-life , and  (2) Large unilamellar vesicles 
(>0.1µm) with high encapsulation efficiency, presumably due to their larger volumes, but 
shorter half-lives (Table 1). In contrast, large multilayered vesicles have an onion-like 
structure formed by the concentric phospholipid layers separated by an aqueous layer. They 
are mechanically stable, but have moderate encapsulatin efficiencies and are cleared rapidly 
by the RES  40.  
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Table 1: Size range of liposomes 
Liposome Subcategory Size range (nm) 
Multilamellar vesicles  >100nm 
Unilamellar vesicles Small Unilamellar vesicles 20-40 
Large Unilamellar Vesicles 100-1000 
 
History of liposomes 
1st generation liposomes 
The first generation of liposomes, the “classical liposomes”, were considered to be naked 
formulations as they lacked a surface grafted with the protective molecule such as 
polyethylene glycol, texposing them to the external environment. Classical liposomes 
demonstrated short half-lives upon intravenous injection and were susceptible to opsonins 
and protein adsorption on the surface, marking the liposomes clearance by the 
reticuloendothelial system (RES)41,42. Some studies also found that the short half-life of 
classical liposome was in part due to the self-aggregation in the systemic circulation. To 
overcome these barriers, in later years, the liposomes were modified by altering the lipid 
composition with neutral rather than anionic/charged lipids, long-chain high phase transition 
lipids, and cholesterol in the bilayer 43. In particular, the incorporation of the cholesterol was 
critical for the tight packing of lipid acyl chains to create a less fluid membrane, resisting 
opsonization and consequently increasing their plasma half-life44,45. Additionally, the 
inclusion of sphingolipids in cholesterol-based liposomes further enhanced the liposomes 
stability by forming hydrogen bonds with cholesterol, increasing membrane rigidity and 
decreasing opsonization. Furthermore, the addition of a small amount of negative charge 
from lipid-like phosphatidylglycerol prevented aggregation and clearance rates41.  Although 
these innovations were promising advances, the half-livers were still sub-optimal, eventually 
paving the way for the second generation long-circulating liposomes as described below 46-49.  
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Second Generation liposomes  
The second generation of liposomes as Stealth® or PEGylated liposomes showed superior 
retention and delayed detection by the RES. These liposomes incorporated ganglioside 
(GM1) and biocompatible polymers, particularly poly (ethylene glycol) (PEG)50-53. 
Typically, PEGylated/Stealth® liposomes were formulated with ~5-10 mol% (total 
phospholipid) of polyethylene glycol (PEG) with molecular weights in the range of 2,000-
5,000 Daltons46,54. PEG’s are non-toxic, and moderately- immunogenic. The long chains on 
the PEG molecules that were hydrophilic could form an aqueous shell around the surface of 
the liposome, reducing self-aggregation42,55,56. The surface grafting of PEG also weakened 
the Van-der-Waals forces that attracted opsonins to the lipid membrane, reducing uptake of 
liposomes by RES52,57,42. Other theories proposed for de-opsonization included binding to 
certain proteins to shield the lipid charges resulting in delayed detection by RES58,59. 
Examples of 2nd generation liposomes included Doxil/Caelyx that passively accumulate in 
the tumor microenvironment by exploiting EPR, however, recent studies have found that the 
poor intratumoral accumulation (~10%) and release rates are the rate-limiting process, 
impacting the overall clinical efficacy4760.  
Third generation of liposomes 
With the advancements in liposomal research, the need for targeting and triggered release of 
encapsulated content in the tumor milieu gained prominence, leading to the development of 
the third generation of liposomes. Examples of 3rd generation liposomes include antibody 
decorated, pH-sensitive, thermosensitive, fusogenic and cationic liposomes. Each of these 
approaches has merit and can be used for a variety of indications as shown in Table 261.  
Table 2: Liposomal drug combinations in clinics list  
 Particle Trade name Approved 
year 
Drug Indication Ref 
1 Lipid 
complex 
Abelcet 1995 Amphotericin B Invasive severe 
fungal infection 
62 
2 Lipid Amphotec 1996 Amphotericin B Severe fungal 63-65 
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complex infection 
3 Liposome Ambisome 1997 Amphotericin B Presumed 
fungal infection 
63 
4 Liposome DaunoXome 1996 Daunorubicine AIDS related 
Kaposi’s 
sarcoma 
66,67 
5 Liposome DepoCyt 1999 Cytarabine Neoplastic and 
lymphomatous 
meningitis 
68,69 
6 Liposome DepoDur 2004 Morphine 
Sulphate 
Pain 
management 
70,71 
7 Liposome Exparel 2011 Bupivacaine Pain 
management 
72 
8 Liposome Epaxal 1993 Inactivated 
Hepatitis A 
virus(strain 
RGSB) 
Hepatitis A 73,74 
9 Liposome Inflexal 1997 Inactivated 
hemagglutinin 
of Influenza 
virus strain A 
and B 
Influenza 75,76 
10 Liposome Myocet 2000 Doxorubicin Metastatic 
breast cancer 
77,78 
11 Liposome Marqibo 2012 Vincristine Acute 
lymphoblastic 
leukemia 
79,80 
12 Liposome 
Photo-
dynamic 
Visudyne 2000 Verteporphin Macular 
degeneration, 
choroidal 
81 
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therapy neovascularizat
ion 
13 PEGylated 
Liposome 
Doxil 1995 Doxorubicin Kaposi’s 
sarcoma, 
Ovarian and 
breast cancer 
82,83 
14 PEGylated 
Liposome 
Lipodox 2013 Doxorubicin Kaposi’s 
sarcoma, 
Ovarian and 
breast cancer 
83-85 
15 PEGylated 
Liposome 
Onivyde 2015 Irinotecan Combination 
therapy with 
fluorouracil and 
leucovorin in 
metastatic 
adenocarcinom
a of the 
pancreas 
86,87 
16 Liposome Mepact 2004 Mifamurtide High grade 
resectable, non-
metastatic 
osteosarcoma 
88-90 
17  Lipid 
complex 
Estrasorb 2003 Estradiol topical 
emulsion 
Menopausal 
therapy 
91,92 
 
We specifically focus on the thermosensitive liposomes in this dissertation93.  
Low temperature sensitive liposomes (LTSLs) 
LTSLs were developed for targeted active delivery of encapsulated cargo at elevated 
temperature61. LTSLs were first introduced by Yatvin et al in 1978 94. LTSLs can be made by 
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lipids such as DPPC, Myristoylstearoyl phosphatidylcholine (MSPC) and PEG conjugated 
lipid, and have phase transition temperature ~40°-45°C. At these temperatures, LTSLs attain 
sharp thermal transition, causing rapid gel-to-liquid phase transitions, and enhanced 
membrane permeability95 releasing the encapsulated drug. LTSLs primarily release contents 
in the blood vessels within tumors, thereby increasing the accumulation of drug-cargo in the 
tumors. An example of LTSL in clinical trials is Thermodox® that was developed by Celsion 
Corporation. Thermodox is in phase III clinical trials for doxorubicin chemotherapy of 
primary liver cancer (hepatocellular carcinoma) and recurring chest-wall breast cancer 95. 
Thermodox was shown to result in a 5-fold higher doxorubicin concentration in blood 
compared to non-thermal sensitive Dox liposomes and 25-fold greater accumulation of the 
drug in the treatment area than intravenous administration of doxorubicin alone96. 
ThemoDox® is composed of DPPC, MSPC and 1, 2-distearoyl-sn-glycero-3-
phosphoethanolamine-N- [amino (polyethylene glycol)-2000] (DSPE-PEG-2000) with a 
phase transition temperature of ~ 41.5°C. The addition of MSPC is crucial for the slight 
reduction in the transition temperature of DPPC, while DSPE-PEG-2000 enhances the 
circulation time of liposomes. The presence of PEG-lipid helps in attaining lysolipid-induced 
permeability at a faster rate97.  ThemoDox® was primarily introduced in the market for 
systemic treatment in combination with Radio-Frequency Ablation (RFA), but recent studies 
have expanded their use with other hyperthermia modalities such as microwave hyperthermia 
and/or High Intensity Focused Ultrasound (HIFU) 98.  Overall, LTSL can control drug 
release99, and reduce non-specific toxicities by spatially and temporally controlling local 
release in tumors.  
Role of High intensity focused ultrasound (HIFU) in localized tumor heating 
HIFU is a non-invasive, non-ionizing modality for inducing thermal and non-thermal effects 
in biological tissue100. HIFU was first used to ablate inoperable brain tissue to manage 
Parkinson's disease. Unfortunately this therapy was not completely developed at that time 
due to lack of  necessary imaging devices101.  HIFU precisely deliver focused ultrasound 
energy locally in the body, sparing the healthy tissues. At the focal point of the ultrasound 
field, contraction and rarefaction of sound waves cause mechanical stress and strain.  By 
varying the parameters such as the pressure amplitude, pulse repetition frequency, 
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propagation length, and power, the resultant sound waves achieved thermal or non-thermal 
outcomes102, coagulative necrosis, ablation, mild-heating, and tissue vaporization or a 
combination of multiple effects103.  
In this dissertation, we utilized HIFU for mild hyperthermia (~40-45°C) generations for 
active drug release from LTSL’s and immune modulation.  
Factors governing mild hyperthermia based treatment responses in tumors 
 
Hyperthermia is an innovative approach for enhancement of therapeutic efficacy in 
combination with chemotherapy and radiotherapy104. Hyperthermia also is leveraged for 
inducing drug delivery from nanoparticles105. In 1984, Sapareto and Dewey reported an 
effective reduction in tumor growth by uniformly heating tumors at 42°C for an hour106. 
Hyperthermia was thought to affect tumor sensitivity to other treatments by direct effect on 
immune cells, change in pH, alterations of tumor vasculature, and release of Heat Shock 
Proteins (HSP’s) and exosomes, and are shown in Figure 1107,108. 
Physiological effects of hyperthermia on tumor blood vessel 
Unlike healthy tissues, the tumor vasculature is abnormal and devoid of smooth muscle. 
Thus, when tumors are heated with hyperthermia, the result is vasodilation, enhanced 
membrane fluidity and vascular permeability resulting in hemorrhage and occlusion. 
Previously, it was believed that tumor vasculature was more susceptible to occlusion and 
hemorrhage compared to normal tissue. However, recent studies have established that tumors 
vasculatures demonstrate similar behaviors to normal tissue when subjected to mild 
hyperthermia (41-42°C) and increase the blood flow by 1.5 to 2 times in the treated regions 
compared to untreated regions109.  Further, Horseman et al and Dewhirst et al. showed that 
hyperthermia increased tumor oxygenation, that in turn impacted chemotherapeutic 
outcomes110. Additionally, the increased blood flow to the target region was found to 
augment the liposome circulation in the tumors 93 and mediate drug release from TSLs. 
Furthermore, hyperthermia enhanced perfusion altered the immune environment and 
trafficking of immune cells such as dendritic cells and T cells between tumors and lymph 
nodes111.  
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Role of hyperthermia in modulating tumor cell profiles 
Exposure of cancer cells to temperatures from 39 to 45°C can change the cell membrane 
fluidity to affect active and passive diffusion, intracellular Na+ and Ca2+ levels, and the 
overall membrane potential, without directly impacting the cell viability112,113. Hyperthermia 
also induces cytotoxic effects via denaturation and aggregation of enzymes such as 
synthetases and polymerases114,115. These enzymes are important for DNA polymerization 
and de novo synthesis, and thus their denaturation by hyperthermia impact the DNA repair 
causing cell cycle arrest and death116. Hyperthermic exposures has also shown to increase the 
surface expression of MHC class I polypeptide-related sequence A (MICA), an NKG2D 
ligand on tumor cells, enhancing the sensitivity of cells to lysis by Natural Killer (NK) cells 
117. Ito et al showed that exposing cells in-vitro to 43°C for 30 minutes enhances recognitions 
by the CD8+ T cells via surface expressed Major histocompatibility complex (MHC) class I 
molecules118. Therefore, hyperthermia generates a multitude of changes in the membrane 
dynamics of tumor cells, altering the permeability and the inflammatory profiles of the tumor 
cells.  
Relationship of hyperthermia exposures of immune cells with cellular processes 
Hyperthermia stimulates the lymphocytes to improve survival from infections and tumor 
growth119. Local and systemic hyperthermia mimics fever to enhance the body’s natural 
response to inflammation120,121. For example, phagocytosis activity in murine macrophages 
briefly treated with hyperthermia (40°C) was found to be enhanced by approximately 40% 
compared to cells cultured at 37°C 122. Likewise, the migration of the epidermal dendritic 
cells (DC’s), also known as Langerhans cells, to lymph nodes and interactions with T-cells 
was found to be significantly increased with heat123. DC’s derived from murine bone marrow 
(BALB/c (H-2d))mice treated with mild hyperthermia (39-40°C) for 3hours decreased the 
secretion of IL-10 and Tumor Necrosis Factor (TNF-α) by maturing DC’s.  While the 
produced IL12, a cytokine responsible for stimulation of the innate immune system (like 
Natural killer (NK) cells, which are a type of lymphocyte that plays an important role in 
rejection of tumors) and cells of the adaptive immune system (T and B cells) was enhanced 
124. This is not always consistent, and studies conducted in BALB/c mice lacking heat shock 
factors (Hsf) kept in a cage at 42°C for 20 minutes reported no changes in the expression of 
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IL-12125. Overall, the cellular stress from hyperthermia treatment has the potential to elevate 
the activity of antigen presenting cells (APC’s) like DC’s and macrophages, which can affect 
the downstream activation of T cells to reduce immune-tolerance to tumors.  
Heat shock proteins (HSP’s) expression is highly correlated with tumor hyperthermia 
Hyperthermia has been found to induce heat shock protein (HSP) expression in cancer cells. 
HSP’s are a heterogeneous group of molecular chaperones and are upregulated in tumor cells 
upon thermal stress126. In contrast to short duration (<1min) ablative range temperatures, 
long-duration hyperthermia (>15min) is relatively more stimulatory for surface expression of 
HSP on cancer cells, presumably due to slow activation of expression profiles over time111. 
HSP’s are subdivided into groups based on their molecular size such as Hsp40, Hsp60, 
Hsp70, Hsp90 and Hsp100-110, among which Hsp 70 is proven to be immunostimulatory127. 
Hsp70 binds to the Toll-like Receptors (TLR) 2 and 4 on DC’s and stimulate NK cell 
proliferation and cytolytic activities are considered to have a high immunostimulatory 
activity127,128. It has been shown that Hsp70 released/ attached to proteins on dying tumor 
cells is directly taken into DC’s and may therefore chaperone antigens directly into DC’s 129. 
Shrivastava et al have shown that those DC’s are able to cross present the tumor antigens 
from Hsp tp CD8+ T cells inciting a CD8+ T cells response against tumors MHC-I 
presentation130-132. While HSPs are considered immunostimulatory, negative role of HSP’s in 
suppressing tumor growth are also reported for example Hsp90 represses tumor suppressor 
protein p53 and block apoptosis of cancer cells133. The amount and type of HSP expression is 
discretely controlled by temperature. For instance, B16F10 melanoma cells heated for 30min 
start to release the HSP70 at 41°C, reaching the peak expression at 43°C and stopping at 
45°C 134. Thus, a careful choice of temperatures can potentially tune the HSP release and 
functional outcomes.  
Hyperthermia is a critical mediator of exosome release from tumor cells 
Exosomes are small 30-100nm membrane vesicles that are released from cells for 
intercellular signalling135. Exosomes released from tumor cells thermal stress can serve as 
immunostimulatory factors enriched with tumor antigens136. Exosomes released in response 
to thermal stress activate the DC and cross-priming of tumor-specific CD8+ T cells. Cao et al 
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demonstrated that exosomes from hyperthermia treated cells activated DC’s and T cells due 
to the expression of chemokines such as CCL2, CCL3, CCL4, CCL5, and CCL20137. 
Consequently, exosomes from heated tumor cells acted as in-built vaccines, enhancing the 
antitumor immune response. 
Cancer and the immune system 
In 2013, Science magazine declared cancer immunotherapy as the “2013 Breakthrough of the 
year” due to exceptional treatment outcomes in cancer patients138.  Cancer immunotherapy 
utilizes the body’s immune system to reverse the immune suppressive pathways to produce 
long-lasting anti-tumor immunological memory.  
The immune system is broadly divided into the innate and adaptive immune system. The 
innate immune system is nonspecific and relies on the action of phagocytes (e.g. 
macrophages; reference). In contrast, the adaptive system uses T cells and B cells to provide 
protection against foreign pathogens. The adaptive immune system is made up of two arms: 
humoral immunity and cell-mediated immunity. Humoral immunity is B cell dependent, and 
eradicates foreign toxins and microbes via antibodies circulating through the body. Cellular 
immunity is coordinated by the T cells, and such cells eradicate foreign agents upon antigen 
presentation by the APC’s.  
The crosstalk between the innate and adaptive immune systems is the key to responses 
against cancer cells. The humoral immunity activates effector T-cells, other endogenous 
immune cells and antibodies against the tumors. Additionally, the DCs serve as the major 
histocompatibility complex (MHC) class–II APCs presenting antigens to a cluster of 
differentiation 8+ (CD8+) T cells to mount cytolytic responses against cancer cells138. The 
interplay of cellular signaling is critical for the priming and activation in the lymph nodes 
and trafficking to the tumor beds for the recognition of the cancer cells by the effector and 
memory T cells139. Although well-orchestrated, antitumor immunity is influenced by the 
tumor microenvironment immune cells, and are described below. 
 (a) Neutrophils: Neutrophils are the most abundant type of innate cells and are known as 
the first line of defense for the detection for the elimination of a foreign pathogen. 
Neutrophils release granules containing antimicrobial peptides and proteases, and 
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extracellular neutrophil traps (NETosis) to aid cellular phagocytosis140.  The role of 
neutrophils in cancer is controversial as it is associated with poor outcomes and aggressive 
cancer phenotypes in some cases141. Such neutrophils are typically of the myeloid origin and 
inhibit the T-cell response and accumulation via multiple pathways such as lowering the 
FcγR(immunoglobulin (Ig) G immune complex receptor)-mediated neutrophil and activation 
macrophage-1 antigen (MAC-1)142,143. Neutrophils also releases Neutrophil Elastase (NE), 
Neutrophil collagenase (MMP8) and Gelatinase (MMP9) factors that promote remodeling of 
the extracellular matrix in tumors, drug resistance and cancer progression 144.  
(b) Myeloid-derived suppressor cells (MDSC): MDSCs are a heterogeneous subset of cells 
of myeloid origin that expand during cancer, inflammation, and infections. Myeloid cells in a 
healthy person differentiate into mature granulocytes, macrophages or dendritic cells (DC’s). 
In cancer patients, myeloid cell differentiation is partially blocked, so the MDSC’s are 
somewhat immature and suppresses T-cell response, promoting tumor angiogenesis and 
modulating cytokine production from the macrophages 145-147.  
(c) Macrophages: Macrophages are the most important arm of the innate immunity, and are 
present in a high population in the tumor microenvironment.  The resident macrophage 
population in tumors can be differentiate into a pro-inflammatory, anti-microbial (M1) and 
anti-inflammatory (M2) subset. The M1 phenotype is stimulated in the presence of 
lipopolysaccharide (LPS), interferon-γ (IFN-γ), and granulocyte-macrophage colony 
stimulating factor (GM-CSF). Anti-inflammatory (M2) phenotype is dominant in the 
presence of macrophage colony stimulating factor (M-CSF), IL-4, IL13, IL-10, 
immunosuppressive agents such as corticosteroids, vitamin D3 and prostaglandins148. M1 
macrophages produce copious amounts of pro-inflammatory cytokines upon activation by 
bacterial products and thus are capable of effective tumor suppression. In contrast, the M2 
macrophages induce tumor progression by undertaking scavenging, matrix remodeling, tissue 
repair and angiogenesis 149.  
(d) Cytotoxic T-Lymphocyte-associated protein 4 (CTLA-4):CTLA-4 on T-cells binds to 
the B7 molecule on dendritic cells and other APC’s inhibiting auto-immune inflammation150. 
CTL4s are an endogenous regulator of T-cell function and increase the activation threshold 
of T cells, increasing immunological tolerance and weakening immune responses against 
14 
 
tumor antigens. CTL4 also promote immune suppression on bystander cells via Tregs, 
indirectly diminishing signaling through co-stimulatory receptor CD-28 151. CTLA-4 and 
CD28 are expressed on the surface of T cells and have higher affinity for CD80 and CD86 
present on APC’s, reducing their availability152.  This blocks stimulatory activity of CD28 
increasing the activation of threshold of T-cells and reducing the immune response to weak 
tumor self antigens153.  
(e) Programmed death-1 (PD-1): PD1 is a transmembrane protein expressed on T cells, B 
cells and natural killer (NK) cells. It is primarily involved in regulating adaptive immune cell 
response and inhibiting immune signaling and is homologous to CD28 154. It binds to the 
programmed death ligand 1 and 2 (PDL-1&PDL-2). Both of these ligands are found on the 
surface of APC’s such as dendritic cells, macrophages and monocytes and non-lymphoid 
tissues (example)155. Binding of PD-1 to PDL receptors causes peripheral T-effector 
exhaustion, promotes conversions of T-effector cells to Tregs, and directly inhibit tumor cell 
apoptosis138156.  
(f) Regulatory T cells (Treg):  Tregs are a unique subset of FOX-P3+CD25+CD4+ 
expressing T cells that suppress the effective antitumor immune response. The normal 
physiological function of Treg is to sub-due autoimmune response in the body by 
suppressing self-antigens157. The abundance of Tregs in tumors correlates with poor clinical 
prognosis158. Tregs suppress conventional T cells, and influence the function of DC’s, 
macrophages, B cells, and NK cells159. IL-2, IL-2 receptor subunits and CTLA-4 (cytotoxic 
T-lymphocyte-associated protein 4) are the most significant molecules impacted with the 
Treg suppression. Treg is also identified by the MHC/self- peptide ligand that has a greater 
affinity for the TCR (T-cell receptors), influencing the activity of IL-2 and CTLA-4160. 
CTLA-4 on the Treg can also downregulate the expression of CD80 and CD86 molecules on 
DC’s, hindering activation of conventional T cell and suppressing anti-tumor immune 
response 152.  
Bacteria can be a critical link to tumor immune modulation and chemotherapy 
responses 
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Nanomedicine and immunotherapy have undoubtedly improved targeted therapy. However, 
outcomes against advanced stage colon cancer remain challenging due to emergence of drug 
resistance and immune tolerance. Therefore, agents that can help overcome immune escape 
mechanisms is critically needed for robust clinical responses161. 
History of tumoricidal therapies with microbial agents 
           Attenuated bacterial agents have shown to improve outcomes in inflammatory bowel disease, 
cancer, autoimmune disorder, and obesity 162,163. Bacterial genetics can be easily manipulated 
to induce production of the ‘perfect’ anticancer effects in the tumor microenvironment. 
Intracellular bacteria such as Salmonellatyphimurium and Listeria monocytogenes penetrate 
non-phagocytic mammalian cells. The earliest reported use of bacteria as an anticancer agent 
was reported in the writings of Ebers Papyrus by Imhotep in 2600 BC, an Egyptian 
physician. Imhotep recommended a poultice for tumors (swellings) followed by an incision, 
which would inevitably lead to an infection at the tumor site. In early 1813, when bacteria 
had not yet been identified as an infectious agent, it was found that cancer patients who 
developed Clostridium infections with gas gangrene exhibited tumor regression164. 
Subsequently, in 1868 German physician W. Busch cauterized a female patient’s neck tumor 
and placed the woman in bedding previously occupied by a patient suffering from 
“erysipelas,” a Streptococcus pyogenes infection, thus performing the first intentional 
bacterial cancer treatment165. The infected patient’s primary tumor shrunk to half and was 
also observed to be accompanied by the reduced size of lymph nodes in the neck. 
Unfortunately, the patient died 9 days later due to complications of uncontrolled infection166. 
In 1893, William Coley, a young physician in New York reported a significant tumor 
reduction by injecting patients with erysipelas after being inspired by accidental tumor 
regression in an immigrant patient with frequent fever due to an infected tumor 167. Dr. 
Coley’s experimental studies found that injecting live bacteria had strong side effects, and 
thus proposed using a combination of heat-killed Streptococcus pyogenes and Serratia 
marcescens. Such combinationsreduced the strong inflammatory and immune activation of 
bacteria, improving outcomes, and this was later referred to as Coley’s vaccine or Coley’s 
toxin168. Coley treated hundreds of patients with sarcomas, carcinomas, lymphomas, 
melanomas, and myelomas in early to advanced stages, becoming a pioneer in the field of 
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bacterial cancer immunotherapy. Despite the cure and remarkable improvements, Coley’s 
studies were considered anecdotal, inconsistent and unsafe according to current standards of 
clinical trials169. Sixteen different preparations of Coley’s toxin have been used since 1892. 
In 1963, Coley’s vaccine was assigned a new drug status by FDA and strict guidelines were 
set for clinical trials. Eventually, the FDA refused to acknowledge “Coley's toxin as an 
approved drug, paving the way for radiotherapy and chemotherapy to gain greater acceptance 
as the gold standards for cancer treatment. Interestingly, a retrospective study conducted by 
Hoption et al compared data from the Surveillance Epidemiology End Result cancer registry 
to evaluate 10-year survival rates of patients treated by either Coley ‘s toxin or conventional 
treatments with surgery and chemotherapy, and found that patients receiving modern 
conventional therapies did not fare better than patients receiving the treatment initiated by 
Coley over 100 years ago 166.  
Tumor microenvironment provides the optimal niche for bacteria homing 
Bacteria display a number of properties that seem relevant for effective cancer treatment. 
Studies conducted with attenuated strains of Clostridium, Listeria, Salmonella, Shigella, and 
E-coli have shown preferential accumulation and multiplication in the solid tumors 170-175. 
That said, the type of antitumor response with bacterial agents depends on the motility, tumor 
chemotaxis, cytotoxic potential, and pathogen-associated molecular patterns (PAMP). It may 
be noted that the mechanisms of bacterial entry in tumor is yet to be determined, but it is 
speculated that the differences between tumor and normal vasculature and blood flow 
patterns favors the entry and entrapment of bacteria within tumors. Some studies also suggest 
that the  macrophages or monocyte entrap and release bacteria in the tumor 176. These 
processes can be aided by the anaerobic hypoxic microenvironment, enhancing the 
chemotaxis and proliferation within the heterogeneous tumor tissue 177,178. Thus, even a small 
number of bacteria can home and proliferate within the necrotic and hypoxic solid 
tumors179180 . This coupled with  slower clearance from tumors relative to healthy tissues 
could imparts cancer specific targeting179. In nude or SCID relative, a 5-50-fold decrease in 
tolerance to bacteria compared to immunocompetent mice is generally observed, suggesting 
that the T-cell may be playing role in its clearance. The clearance and suppression of 
virulence of bacteria in tumor can also be mediated by the host defenses including 
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macrophage-phagocytosis, antibacterial peptides, antibodies, and elements of the 
complement system, and  physical barriers to the entry of of the infecting pathogens181 182.   
Bacterial agents for tumor therapy 
Currently, Bacillus Calmette-Guerin (BCG) is the only bacterial agent approved by the FDA 
for the treatment of superficial, non-muscle invasive bladder cancer (NMIBC). BCG is 
highly effective in high-risk NMIBC especially when the live attenuated bacteria is 
administered repeatedly into the bladder183. Unlike Coley’s toxin, BCG does not induce 
fever,  and the local administration appears to outperform chemotherapy likely via the 
stimulation of regional immune response 184. A key challenge of BCG is that its effectiveness 
is limited to superficial bladder cancer. Thus, developing novel bactericidal approaches that 
allow targeting of small and large tumor lesions irrespective of tumor locations are needed, 
and is the focus of the Ph.D. dissertation. 
 
Salmonella typhimurium is a motile, non-spore forming, gram-negative, facultative anaerobic 
bacteria belonging to the family Enterobacteriaceae185. Salmonella species are known to 
cause localized gastrointestinal infections in humans and animals. In 1997, Pawelek et al 
demonstrated that Salmonella preferentially accumulates within tumors and achieves tumor 
to normal tissue ratios of approximately 1000:1 (Table 3). It was observed that the high 
accumulation of Salmonella improved survival rates compared to untreated controls186,187. 
The tumor homing and bactericidal properties of attenuated Salmonella spp. in the quiescent 
and necrotic environment is likely due to the chemotaxis towards the serine, ribose, and 
aspartate that are produced by the quiescent cells within the tumor177. Additionally, the 
irregular vasculature and positive pressure prevent the delivery of antibiotics and serum 
complement in the hypoxic areas of tumor, preventing the Salmonella lysis and resulting in 
increased overall numbers in tumor181. Luo et al showed that Salmonella can accumulate and 
homogeneously distribute in murine tumors as small as 0.05 g to 0.3 g188.  Low et al 
genetically engineered Salmonella to produce VNP 20009/YS1646 strain to overcome 
virulence to render it safe to be used an anticancer agent187. VNP 20009 has msb and pur 1 
gene deletions. pur1 deletions lead to purine auxotrophy, attracting the bacteria to the tumor 
leading to enrichment of the bacteria at that site, whereas msb deletion reduces LPS-induced 
shock by interfering with addition of terminal myristyl group to Lipid A VNP20009 strain 
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also has a significantly reduced capacity to induce TNF-αstimulation and production in the 
host182,187.  
The exact mechanism behind the direct cancer cell killing of Salmonella is still unclear, but is 
attributed to the competition for extracellular nutrients and growth factors within the tumor 
microenvironment, localized production of cytotoxins, and stimulation of the immune 
system189190,191,178,192. Salmonella has been shown to enhance tumor cell gap junction activity 
in melanoma cells (B16F10) by increasing the expression of CX43 proteins. Gap junctions 
are responsible for intercellular communication and are often absent on the tumor cells 193. 
Thus, increased expression of CX43 proteins upon Salmonella injection facilitates the 
passage of antitumor drugs and trigger death signal between adjacent tumor cells 193. This is 
especially evident in the first 24-48h, suggesting a role of CX43 proteins upregulation and 
apoptosis induction. The enhanced colonization of Salmonella in the hypoxic regions 
disables the bactericidal activity of the macrophages and neutrophils194. This is evidenced by 
an absence of effector granulocytes in tumor biopsies, and lack of growth factor β that is 
produced by tumor cells for the activation of the innate immune system 195. LPS present in 
the cell wall of gram-negative Salmonella can activate TLRs to initiate a pro-inflammatory 
cytokine production that recruits immune cells at the tumor site 196,197. CD8+ T cell 
infiltration in tumors increases, because of inflammation against Salmonella present within 
the tumors. The recruited T cells inhibit tumor growth and development via the 
cross‐presentation of tumor antigen by the bacteria. Thus, Salmonella-induced T-cell 
response in the tumor is proposed to be against both Salmonella and tumor antigen 193. 
Additional contributing factors to antitumor efficacy include the type III secretion 
mechanism, that causes the delivery of toxic peptides from the bacterial cytoplasm directly 
into the cytoplasm of mammalian cells, selective intra-tumoral intravascular coagulation of 
tumors,  and production or secretion of toxins into the extracellular environment 198. Thus, 
Salmonella typhimurium(YS1646) is a tumor homing microbe with excellent potential to 
increase tumor immunotherapy.  
 
Use of Salmonella in clinical trials  
Salmonella entered Phase 1 human trials in 2000 for the treatment of metastatic melanoma, 
however, the outcomes weren’t successful 199. Salmonella accumulated focally in two 
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patients out of 25 receiving dose and one patient was reportedly disease free in a follow-up 
study 200. Majority of the patients showed insignificant tumor regression, a consequence of 
the over-attenuation of Salmonella201. Thus, the failure of bacteriolytic therapies to elicit 
significant clinical effect by themselves in humans (despite promising results in murine 
models) highlights the need to develop modified approaches. 
Table 3: Ratio of Colony forming unit of Salmonella accumulating in tumors compared to 
the liver. 179,202 
Tumor type Tumor:Liver (CFU ratios) 
B16 melanoma 9,000:1 
C-8186 melanoma 1500:1 
LOX melanoma 3,000:1 
M27 lung carcinoma 10,000:1 
A549 lung carcinoma 300:1 
HTB177 lung carcinoma 4,000:1 
Murine spontaneous breast tumor 700:1 
MDA-MB-231 breast carcinoma 34,000:1 
SW-620 colon carcinoma 275:1 
HCT 116 colon carcinoma 17,000:1 
DLD1 colon carcinoma 15,000:1 
CAKI renal carcinoma 250:1 
 
Other bacterial Agents 
Magnetospirillum magneticum (AMB-1) 
Magnetospirillum magneticum (AMB-1) is a gram-negative motile magnetotactic bacteria 203.  
AMB is non-pathogenic and naturally orient along the geomagnetic lines to migrate toward 
low oxygen tension area204. The alignment and movement of AMB-1 towards the magnet 
(magnetotaxis) is caused by the presence of magnetosomes within the bacteria205. 
Magnetosomes are crystals of iron oxide particles and organize as chains via a dedicated 
cytoskeleton206.  Each AMB-1 contains approximately 10 elongated cuboctahedral 
magnetosomes in a single chain. The magnetosomes provide a positive or negative contrast 
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on MRI and generate a T1 weighted contrast on MRI207. The magnetosomes can also be 
leveraged to provide thermotherapy with alternative magnetic field208, especially against 
colon cancer209. Complete disappearance of tumor 30 days following treatment was reported 
in MDA-MB-231 mice breast cancer model treated with magnetosomes and Alternating 
Magnetic Field (AMF) induced hyperthermia for 20 minutes210. Magnetosomes can be 
tailored for the delivery of nucleic acids and drugs. For example, cross-linking 
nanoliposomes on the surface of magnetic bacteria Magnetococcus Marinus has been shown 
to improve the targeting of nanocarriers in HCT116 colorectal xenograft211. A key challenge 
of AMB-1 approach is the required peritumoral injections, which may not be suitable 
clinically for deep-seated tumors (Table 4). Interestingly, Benoit et al in 2009 using MRI 
showed that AMB-1 can naturally home to tumors when administered intravenously. They 
found that AMB-1 colonies from other organs such as spleen and liver depleted after 4 hours, 
but were present in tumors by day 6207. Thus,  modifying AMB-1 to attach nanoparticles (e.g. 
LTSL) for specifically delivering therapeutic agents in the tumors can be an innovative 
idea212. Additionally, AMB-1 can aid the cytokine-induced NK cell tracking, thermotherapy, 
MRI imaging, and disease diagnosis213,214.   
Table 4: Summary of magnetic bacteria/ magnetosomes application in drug delivery and 
hyperthermia treatments  
Application Key results Disadvantage Ref 
Magnetic bacteria 
Drug 
Delivery  
Mc Marinus bound to 
nanoliposomes for 
targeted tumor 
treatment  
Cells were magnetically 
guided for delivery to the 
hypoxic  tumor area 
Relied on 
peritumoral 
injection  
211 
MRI contrast 
agent  
AMB-1 injected IV 
was tested for 
contrast development  
AMB-1 colonized in 
tumors and generated the 
T1 weighted positive 
contrast  
Time-
dependent 
accumulation 
with no 
magnetic 
guidance 
207 
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Magnetosomes 
Drug/gene 
delivery 
Delivery of 
doxorubicin, 
cytarabine, 
daunorubicin, 
CercopinB, apoptin 
(VP3) 
 
Reduction in drug 
toxicity and  
enhanced anti-tumor 
effect against hepatic and 
osteosarcoma was noted 
 
Unclear 
biological fate 
with delayed 
drug release 
was noted 215 
215-219 
Hyperthermia  Hyperthermia(~42°-
43°C) treatment in 
combination with 
AMF  
Reduced toxicity with   
improved treatment 
outcomes for 
glioblastoma, colon 
cancer was observed 
 
Long term 
evaluation of 
biological fate 
required 
209,220-
222 
MRI contrast 
agent  
Diagnostic detection 
of tumors; Targeting 
with specific peptides 
Enhanced specificity and 
sensitivity than 
conventional imaging for  
EGFR/HER2+ cells, 
brain, and pancreatic 
tumors were observed223 
 
Long term 
evaluation of 
biological fate 
required 
224-226 
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CENTRAL HYPOTHESIS AND SPECIFIC AIMS of the PhD Dissertation 
 
CENTRAL HYPOTHESIS 
Multifunctional LTSLs would enhance chemo-immunotherapy efficacy and real-time 
monitoring against colorectal cancer  
 
AIM 1: Develop imageable thermosensitive liposomes for real-time estimation of drug 
delivery and tumor temperature 
 
Hypothesis: Predictable change in tumor ultrasound contrast with imageable LTSL and 
hyperthermia treatment can act as surrogate marker for real time tumor temperature and drug 
release.  
 
a. Develop imageable and echogenic LTSLs (E-LTSL) co-loaded with doxorubicin and 
ultrasound contrast agent (perfluoropentane; PFP) for image-guided doxorubicin 
delivery. 
 
b. Compare doxorubicin delivery of E-LTSL with echogenic non-temperature sensitive 
liposomes (E-NTSL) in mouse colon cancer. 
 
c. Correlate ultrasound contrast of E-LTSL and E-NTSL with tumor temperatures 
 
 
AIM 2: Utilize Salmonella as the LTSL carrier for targeting of tumor hypoxic cores, 
and modulation of tumor immune environments 
 
Hypothesis: LTSL-laden Salmonella (Thermobots) in combination with hyperthermia (40-
42ºC) will generate a pro-inflammatory immune environment to improve doxorubicin 
efficacy against colorectal cancer therapy.  
 
a. Attach LTSL to Salmonella via Biotin Streptavidin chemistry to synthesize “thermobots”. 
Evaluate cytotoxicity and cellular uptake of thermobots in vitro.  
 
b. Assess efficacy of thermobots to deliver doxorubicin in combination with High Intensity 
focused ultrasound (HIFU) mediated hyperthermia.  
 
c. Evaluate the immune cell response and doxorubicin efficacy of thermobot treatment in 
combination with (HIFU) hyperthermia in murine colon cancer 
 
 
AIM 3: Augment LTSL delivery with AMB-1 under magnetic guidance to murine colon 
cancer 
 
Hypothesis: LTSLs attached to AMB-1 and targeting with hyperthermia (40-42ºC) and 
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halbach array will improve localized chemotherapy of colon cancer.  
 
a. Optimize LTSL attachment to AMB-1 membrane via Biotin Streptavidin chemistry 
(AMB-LTSL). 
 
b. Evaluate magnetotaxis, imageability and viability of AMB-LTSLs. 
 
c. Determine the cytotoxicity of AMB-LTSL, Dox-LTSL, and AMB-1 with mild 
hyperthermia C26 colon cancer in vitro. 
 
d. Assess efficiency of Halbach array to magnetically guide AMB-LTSL to tumor core 
for doxorubicin delivery. 
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Figure 1: Mechanisms of immune activation with tumor hyperthermia 
Tumor hyperthermia enhances the surface expression of MICA, a NKG2D ligand, and MHC 
class I to improve lysis by natural killer (NK) cells and CD8+ T cells. Heat shock proteins 
(HSPs) and exosomes released from heated tumor cells can be presented by the antigen 
presenting cells (APCs) to CD8+ T cells for tumor cell lysis by the NK cells. Hyperthermia 
can also facilitate trafficking of immune cells in the tumor and draining lymph node.  
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CHAPTER II 
 
 
MOTION COMPENSATED TUMOR IMAGING FOR THERMOMETRY AND 
DRUG DELIVERY MONITORING USING ULTRASOUND IMAGEABLE 
ECHOGENIC LIPOSOMES  
Graphical Abstract 
 
1 Earlier version of this chapter has already been published as Ektate K, Kapoor A, 
Maples D, Tuysuzoglu A, VanOsdol J, Ramasami S, Ranjan A. Motion Compensated 
Ultrasound Imaging Allows Thermometry and Image Guided Drug Delivery Monitoring 
from Echogenic Liposomes. Theranostics 2016; 6(11):1963-1974. 
doi:10.7150/thno.15922.  
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Abstract 
Ultrasound imaging is widely used both for cancer diagnosis and to assess therapeutic 
success, but due to its weak tissue contrast and the short half-life of commercially 
available contrast agents, it is currently not practical for assessing motion compensated 
contrast-enhanced tumor imaging, or for determining time-resolved absolute tumor 
temperature while simultaneously reporting on drug delivery. The objectives of this study 
were to: 1) develop theranostic echogenic heat sensitive (E-LTSL) and non-
thermosensitive liposomes (E-NTSL) to enhance tumoral half-life of contrast agents, and 
2) measure motion compensated temperature induced state changes in acoustic 
impedance and Laplace pressure of liposomes to monitor temperature and doxorubicin 
(Dox) delivery to tumors. LTSL and NTSL containing Dox were co-loaded with an US 
contrast agent (perfluoropentane, PFP) using a one-step sonoporation method to create E-
LTSL and E-NTSL. To determine temperature induced intensity variation with respect to 
the state change of E-LTSL and E-NTSL in mouse colon tumors, cine acquisition of 20 
frames/second for about 20 min (or until wash out) at temperatures of 42°C, 39.5°C, and 
37°C was performed. A rigid rotation and translation was applied to each of the “key 
frames” to adjust for any gross motion that arose due to motion of the animal or the 
transducer. To evaluate the correlation between US intensity variation and Dox release at 
various temperatures, treatment (5 mg Dox/kg) was administered via a tail vein once 
tumors reached a size of 300–400 mm3, and mean intensity within regions of interest 
(ROIs) defined for each sample was computed over the collected frames and normalized 
in the range of [0,1]. When the motion compensation technique was applied, a > 2-fold 
drop in standard deviation in mean image intensity of tumor was observed, enabling a 
more robust estimation of temporal variations in tumor temperatures for 15-20 min. due 
to state change of E-LTSL and E-NTSL. Consequently, a marked increase in peak 
intensity at 42°C compared to 37°C that corresponded with enhanced Dox delivery from 
E-LTSL in tumors was obtained. Our results indicate that echogenic liposomes provide a 
predictable change in tumor vascular contrast with temperature, and this property could 
be applicable to nanomonitoring of drug delivery in real time  
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1. Introduction 
A major challenge in image guided drug delivery (IGDD) is developing accurate means 
to implement real-time drug delivery control with motion compensation. In prior 
research, locally inducible image guided drug release using heat-activated liposomes (low 
temperature sensitive liposomes; LTSLs) that are sensitive to mild, non-destructive 
temperature elevations above normal body temperature (40–42 °C) has been investigated 
1-4. LTSLs can achieve significantly improved drug accumulation and distribution in 
tumors compared to conventional treatment 5-8. Additionally, imageable LTSLs 
containing a combined payload of magnetic resonance (MR) contrast agents (e.g., 
gadolinium, manganese) and doxorubicin (Dox) combined with MR guided high intensity 
focused ultrasound (MR-HIFU) can provide a real-time estimation of tumor 
chemotherapy coverage 4,9-11. This is achieved by mild heating of imageable LTSLs to 
release the contrast agent in order to enhance tumor areas in the MR images to allow 
estimation of the mean amount of anticancer drug (e.g., Doxorubicin or Dox) that has 
been delivered to the cancerous tissue. Mild hyperthermia (40–45°C) is fundamentally 
distinct from hyperthermia-based ablative technologies (> 55°C) that are intended to 
destroy tumor tissue by heating 12. Thus, to achieve maximal LTSL-mediated drug 
release, tissue temperatures must be delicately balanced and precisely controlled with 
feedbacks for real-time monitoring of chemotherapy delivery 13,14.  
The most commonly used method for performing absolute MR-based thermometry is 
based on temperature-dependent chemical shift changes in proton resonance relative to 
that of a reference resonance 15. However, use of MRI is expensive, requires large 
dedicated facilities, and has technical limitations (e.g., interference by target tissue 
movement), and the agents that are required to create tumor imageability (e.g., 
gadolinium) may alter the chemical shift, thereby disrupting the fidelity of temperature 
measurement and drug delivery 16,17. Thus, there is a critical clinical need to develop an 
alternative, less-constrained technology using a modality such as ultrasound (US) that is 
low-cost and portable for accurate IGDD. US imaging is widely used both for cancer 
diagnosis and to assess therapeutic success, but due to its weak tissue contrast and the 
short half-life of commercially available microbubble (MB)-based contrast agents, it is 
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currently not practical for visualizing localized drug release in real time or for 
determining chemotherapy distribution.  
To address the limitations of the short half-life of MBs, recently we developed a 
theranostic echogenic LTSL (E-LTSL) that co-encapsulates the US contrast agent 
perfluoropentane (PFP) and Dox in a size-controlled manner 18,19. PFP is a very 
hydrophobic, nontoxic, noncarcinogenic fluoroalkane with a boiling point (29 °C) 
between room and body temperatures 20. The phase transition temperature for PFP is 
clinically relevant, as it allows PFP to be injected in the form of liquid droplets dispersed 
in an aqueous medium that then are converted to echogenic bubbles upon warming to 
body temperature 21. Moreover, when stabilized by a lipid shell, the Laplace pressure 
(i.e., the pressure difference between the inside and the outside of PFP) substantially 
increases its boiling temperature due to the surface tension at the interface between PFP 
and bulk liquids 22. Based on these features, we hypothesized that the predictable boiling 
point changes of encapsulated PFP with temperature due to Laplace pressure variation 
can be applied to nanothermometry and nanomonitoring of drug delivery. To achieve this 
goal, a robust motion compensation technology for tumor imaging is required to translate 
the contrast intensity variations into quantifiable state changes of nanoparticles.  
In this study, we used our long circulating theranostic liposomes for motion compensated 
vascular contrast determination, and we applied this methodology to evaluate the 
temperature-dependent liposomal state change in combination with US imaging. Finally, 
we applied the predictable change in tumor vascular contrast of theranostic echogenic 
liposomes (thermosensitive [E-LTSL] and non-thermosensitive [E-NTSL]) for 
nanomonitoring of drug delivery. In vivo data obtained from a mouse tumor model 
suggest that co-encapsulated PFP in liposomes can be used to determine the temperature-
dependent state of nanoparticles, and this property could be applicable to nanomonitoring 
of IGDD in real time, especially from E-LTSLs. 
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2. Materials and Methods  
2.1 Materials 
PFP (99%, Exfluor Research Corporation, TX, and USA) was used as the US contrast 
agent. Monostearoyl-2-hydroxy-sn-glycero-3-phosphocholine (MSPC), 1,2-
dipalmitoylsn-glycero-3-phosphocholine (DPPC), and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy (polyethylene glycol)2000] (DSPE-mPEG2000) were 
obtained from Corden Pharma Corporation (CO, USA). Dox was obtained from LC 
laboratory (MA, USA). Agarose and psyllim fiber were purchased from BDH (PA, USA) 
and Konsyl Pharmaceuticals, (MD, USA), respectively. Graphite was purchased from 
Alpha Aesar (Ward Hill, MA, USA). Acetonitrile (HPLC grade) was obtained from 
Pharmco-AAPER (CT, USA). Ethylene glycol (99%, spectrophotometric grade), 
phenylboronic acid (98%), and 2,2-dimethoxypropane (98%) were purchased from Alpha 
Aesar. The PD-10 column was obtained from GE Healthcare Life Sciences 
(Buckinghamshire, UK). C26 cells were kindly provided by the National Cancer Institute.  
2.2 Synthesis of E-LTSLs and E-NTSLs 
LTSLs (lipid composition: DPPC, MSPC, and DSPE-mPEG2000 in the molar ratio of 
85.3:9.7:5.0) and NTSLs (DPPC, cholesterol, and DSPE-mPEG2000 in the molar ratio of 
58.1:36.8:5.07) were prepared by hydration of a lipid film followed by the extrusion 
method described previously 23. Briefly, lipid mixtures were dissolved in chloroform. The 
solvent was evaporated and the resulting lipid film was hydrated in citrate buffer (pH 4.0) 
mixed with 1,3-propanediol (1,3-PD (0.65 M, for PFP emulsification) at 55 0C for 30 min 
and extruded five times through double stacked 200 nm polycarbonate filters to yield a 
final lipid concentration of 50 mg lipid/ml (80.8 mM for LTSLs and 70.3 mM NTSLs)24. 
A PD-10 size-exclusion column equilibrated with 5–10 column volumes of 1x phosphate 
buffered saline (PBS) was used to remove free 1,3-PD from the outside of the liposomes. 
Encapsulation of Dox into the E-LTSLs and E-NTSLs was carried out using the pH 
gradient loading protocol described by Mayer et al. [21]. The outside of the E-LTSLs was 
adjusted (by column) to about pH 7.4 using PBS, whereas the inside remained acidic at 
pH 4. Dox was loaded at 2 mg per 100 mg lipid concentration at 37°C for 1 h. PFP-
loaded E-LTSLs and E-NTSLs were prepared using a one-step sonoporation method. 
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Briefly, 2 mL of the liposomal formulations were incubated under continuous sonication 
(~20 khz) in 3 mL vials along with PFP (boiling point 30°C; 20 μL/100 mg lipid) for 1–2 
min. PFP and LTSLs were kept cold prior to being combined, and the sonication bath 
was kept at 4°C to minimize PFP vaporization. This method was repeated at least in 
triplicate (n = 3) for evaluation. Free Dox and PFP were removed using a PD-10 column. 
For all in vitro characterizations, LTSLs were used as a positive control.  
2.3 Characterization of E-LTSLs and E-NTSLs  
E-LTSLs and E-NTSLs were characterized for size (z-average), polydispersity index and 
zeta potential using dynamic light scattering (DLS) with a 90 plus PALS Nanobrook 
device (Brookhaven Instruments, Holtsville, NY, USA). Briefly, 10–20 µl of E-LTSLs or 
E-NTSLs were added to 2 ml of PBS in a cuvette, and DLS measurements were recorded 
at room temperature. For each liposomal formulation an average of five measurements 
were taken, and the mean size and standard deviation were calculated for the E-LTSLs 
and E-NTSLs samples. 
2.4 Dox release from E-LTSLs and E-NTSLs 
Stability at body temperature (37°C) was assessed by measuring release of encapsulated 
Dox from E-LTSLs and E-NTSLs as a function of temperature (25–42°C) in PBS. E-
LTSLs (50 mg lipid/ml) and E-NTSLs (50 mg lipid/ml) were diluted 300 fold in PBS, 
and 3 mL of sample were placed in a quartz cuvette equipped with a stopper and 
magnetic stirrer. Fluorescence of the released Dox was recorded at an excitation 
wavelength of 480 nm and fluorescence emission at 590 nm using a Cary Eclipse 
Fluorescence Spectrometer (Agilent Technologies, Santa Clara, CA, USA) equipped with 
an inbuilt temperature control system. Fluorescence readings were recorded for every 
degree ramp in temperature of the sample from 25 to 42 0C. 
Drug release based on fluorescence quantification as a function of change in temperature 
was determined using the equation below: 
%  	
		 =  It − IoIm − Io × 100 
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where Io is the initial fluorescence intensity for E-LTSLs and E-NTSLs in suspension at 
25°C, It is the intensity of the same sample at a predetermined temperature, and Im is the 
fluorescence intensity of completely released Dox from E-LTSLs at 45°C or from E-
NTSLs post breaking of the liposomes with 10x triton.  
2.5 Transmission electron microscopy (TEM) imaging of E-LTSLs and E-NTSLs 
TEM with negative staining was used to image E-LTSLs and E-NTSLs at various 
temperatures. Briefly, E-LTSLs and E-NTSLs were heated at 37°C, 39.5°C, and 42°C in 
a water bath for 15 min. The heated liposomes were diluted 500–1000X in PBS, and 10 
μl of sample were loaded onto a carbon grid (Lacey and Holey grid). The grid was 
allowed to dry for 30 seconds followed by a 30 second treatment with 9 μl of 2% 
phosphotungstic acid. All TEM images were captured at 200 kV using a JOEL JEM-2100 
TEM (JEOL, Peabody, MA, USA). 
2.6 Monitoring of E-LTSL and E-NTSL intensity in an agarose phantom model 
For US imaging, the phantom recipe (3% (w/v) agarose and 0.25% (w/v) graphite) was 
optimized to withstand hyperthermia temperatures up to ~70°C. Prior to imaging, free 
PFP was removed from E-LTSLs and E-NTSLs using PD-10 columns, and 1 ml of 
liposomes (~20–30 mg of total lipid) was added to the phantom wells for imaging. The 
phantom wells were positioned vertically in an Isotemp water bath (Fisher Scientific, 
Pittsburgh, PA, USA) with the visualsonics ultrasound transducer MS250 (13–24 MHz) 
positioned obliquely against the wells. Temperatures of the phantom wells were recorded 
before initiating imaging and during imaging using thermocouples positioned at the top 
of each well ~1 cm below the sample surface. Each minute the water temperature was 
increased by 1°C. Unpurified PBS mixtures containing PFP were used as positive 
controls. Column-purified PBS mixtures containing PFP alone or 1,3-PD plus PFP were 
used as additional controls.  
To evaluate the correlation between US intensity and Dox release at various 
temperatures,a cine acquisition of 100 frames at 20 frames per second was acquired for 
each temperature point simultaneously for E-LTSLs and E-NTSLs. Mean intensity within 
regions of interest (ROIs) defined  for each sample was computed over the collected 
frames and normalized in the range of [0,1]. Data were fitted with two exponential curves 
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using the least squares method, one for each part between 31 and 39°C and 39 and 45°C, 
respectively. The inflection point was determined by the rapid change in intensity of the 
two fitted curves. 
2.7 In vivo US imaging setup and hyperthermia treatment protocol 
All animal-related procedures were approved and carried out under the guidelines of the 
Oklahoma State University Animal Care and Use Committee. For tumor initiation, C26 
colon carcinoma cells were established in athymic nude mice as previously described 
18,19. Briefly, confluent C26 cells grown as a monolayer in RPMI medium supplemented 
with 10% v/v fetal bovine serum and 1% v/v streptomycin/penicillin were harvested, 
washed, and diluted with sterile cold PBS at 0.5x 105 cells/50 μl. Next, 50 μl of cell 
inoculum were injected subcutaneously in the thigh region of the mouse hind leg with a 
25-gauge needle (BD; Franklin Lakes, NJ, USA). Mice were monitored and tumor 
growth was measured by serial caliper measurements (General Tools Fraction+™, NY, 
USA). Tumor volumes were calculated using the formula (length X width2)/2, where 
length is largest dimension and width is the smallest dimension perpendicular to length.  
Tumor imaging was initiated once the tumors reached a volume of 300-400 mm3. For 
imaging, mice were anesthetized with 2–5% isoflurane and then secured on a heating 
stage maintained at 37°C (Stryker, MI, USA). For imaging, only the tumor bearing leg 
was isolated in specialized holders and immersed in the water bath, which was 
maintained at the desired temperatures of 37, 39.5, or 42°C. Tumor temperatures were 
allowed to equilibrate with the water bath for 10–15 min before injection of E-LTSLs/E-
NTSLs. The water bath temperature was set 1°C higher relative to the target temperature, 
as this had already been calibrated to yield mean tumor temperatures of 37, 39.5, and 
42°C.   
2.8 Image acquisition procedure 
For in vivo studies, all US imaging was conducted using a VisualSonics Vevo 2100 
ultrasound MS550D transducer (22–55 MHz) (22–33 MHz, Fujifilm, Toronto, ON). For 
imaging, the transducer was placed in a stationary position oblique to the tumor with 
special clamps built in-house. Mice were injected with 100μl of E-LTSLs or E-NTSLs 
(~10 mg total lipid) followed by 50μl of saline flushed through a catheter placed in the 
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tail vein. To assess image intensity over time, a cine acquisition of 100 frames at 20 f/sec 
was acquired at different time points up to 15–30 min. 
2.9 Motion compensation for image intensity determination 
To assess motion correction in the in vivo model and determine the variation of image 
intensity over time, a cine acquisition of 100 frames at 20 f/sec was acquired at different 
time points up to 15 min in our mouse model (Fig. 8a). A ROI encompassing the tumor 
was defined in the first frame and tracked in subsequent images by applying a rigid 
translation and rotation to the ROI to maximize the similarity between ROIs in each 
successive frame pair. Multiple ROIs were selected to include the region of tumor as well 
as other areas with high feature variations. In cases in which the tumor region did not 
have sufficient features to reliably compute similarity measures, alternative feature-rich 
ROIs were used. The rigid transformation computed using the alternative ROI was then 
applied to the tumor ROI. Similarity between ROIs was computed using Normalized 
Cross-Correlation (NCC). Once motion corrected, ROI sequences were analyzed over 
time as median intensity over the ROI normalized to the range [0,1]. This averaging 
method provided implicit regularization for noise and allowed determination of general 
characteristics of the ROI (peak intensity, rise time). 
2.10 Validation of temporal vascular intensity variation of liposomes under motion 
compensation with temperature for drug delivery monitoring 
To validate intensity variation with respect to temperature and the state change of the E-
LTSLs and E-NTSLs in the mouse tumor, acquisition of 100 frames at temperatures of 
37, 39.5, or 42°C (n=5-6 per temperature point) was performed. The temperature was 
kept constant for about 20 min (until wash out) at 42°C and then lowered to 39.5°C, 
followed by another injection of E-LTSLs. For each of these datasets, motion 
compensation was applied to each of the image frames as described in section 2.9. ROI 
sequences were analyzed to result in one median “key frame” per time period. 
Subsequently, a rigid rotation and translation was applied to each of these key frames to 
adjust for any gross motion that arose due to motion of the animal or the transducer by 
maximizing NCC between consecutive key frames. The normalized intensity visualized 
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as a function of time allowed determination of general characteristics of the peak 
intensity, wash-in AUC—wash-out AUC) for each of the temperature points.  
2.11 Nanomonitoring of drug delivery and Dox quantification by high performance 
liquid chromatography (HPLC) 
For nanomonitoring, the tumor was kept at fixed temperatures of 37 and 42°C in a water 
bath. After the baseline ultrasound images of target tumor was obtained, the mice were 
injected with Dox-loaded E-LTSLs or E-NTSLs, and US images were collected to 
confirm intensity variation. One hour following treatment, mice were euthanized, and 
cardiac perfusion was performed. The tumors and other organs were excised, weighed, 
snap frozen over liquid nitrogen, and then stored at –80°C until HPLC was performed to 
estimate the amount of drug in the tumor samples (n=3-5/treatment group).  
For HPLC, stock solutions of Dox (0.25–100μg) and internal standard (Daunorubicin; 
2.5μg/ml) were prepared in deionized water1. For calibration standards, a tumor from a 
control mouse was spiked with 10μl of Dox (0.25–100μg Dox/ml) and Daunorubicin 
(2.5μg/ml). Tumors were homogenized in aqueous KH2PO4 solution (20mM, pH 3.8) at a 
concentration of 100 mg/ml with zirconia beads (2 mm diameter, Biospec Products Inc., 
OK, USA) with Mini-Beadbeater-16 (Biospec) at 3450 oscillations/min for 3 min. For 
HPLC analysis, 90μl (n = 3, 100 mg/ml) of the tumor homogenate were mixed with 50μl 
of internal standard solution (2.5μg Daunorubicin /mL) incubated at 37°C for 15 min. 
Post-incubation, 250μl of acetone and 100μl of ZnSO4 solutions (saturated) were added 
to the homogenate, and it was re-incubated at 37°C for another 15 min to precipitate the 
proteins. Subsequently, the samples were centrifuged in a Microfuge 22R (Beckman 
Coulter, CA, USA) at 18110 x g at 4°C for 10 min. Finally, 200µL of supernatant were 
transferred to another vial and evaporated using TurboVap LV (Caliper Life Sciences, 
MA, USA) at 60°C under a stream of compressed air. Prior to HPLC, the dried residue 
was completely dissolved in 100μl HPLC mobile phase, and 20µL of this solution were 
introduced into the Shimadzu HPLC system for analysis. 
2.12 Statistical analysis 
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Treatment groups were compared for differences in mean Dox concentration using 
analysis of variance (ANOVA) followed by Tukey’s multiple comparison post-hoc test. 
All analyses were performed using GraphPad Prism 5.0 (GraphPad Software Inc.). All p-
values were two-sided, and a p-value < 0.05 indicated statistical significance. Values are 
reported as mean ± SEM unless otherwise indicated. 
3. Results 
3.1 Characterization of E-LTSLs and E-NTSLs 
Active loading of Dox by transmembrane pH gradient yielded an encapsulation 
efficiency of ~95% and ~65% for E-LTSLs and E-NTSLs, respectively. Following PFP 
loading by one-step sonoporation, E-LTSLs and E-NTSLs retained about 70–80% of the 
encapsulated drug. Table 1 shows the hydrodynamic diameter, polydispersity index and 
zeta potential values of E-LTSLs and E-NTSLs at room temperature (25°C), and these 
were fairly similar between various groups following PFP loading.  
Table 1: Physicochemical characterization of E-LTSL and E-NTSL 
3.2 Dox release from E-LTSLs and E-NTSLs in physiological buffer 
Percent Dox release from E-LTSLs and LTSLs was minimal (< 5%) at 25–39°C, more 
gradual at 40°C (~20%), and rapid and complete (> 95%) near the temperature with the 
maximum release rate (~41–42°C) (Fig. 1). In contrast to E-LTSLs, Dox release from E-
NTSLs and NTSLs was < 5% at all temperature points tested, which confirms their non-
thermosensitivity. 
3.3 TEM analysis of E-LTSLs and E-NTSLs 
TEM confirmed the presence of PFP and 1,3-PD emulsion within the liposome aqueous 
core between 37°C to 42°C for E-LTSLs (2a-c) and E-NTSLs (2d-f). E-LTSLs and E-
NTSLs were spherical at 37°C, but the membranes deformed at ~42°C. In general, 
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membrane deformation of E-LTSLs at 39.5°C and 42°C was more prominent compared 
to E-NTSLs. 
3.4. Intensity variation of E-LTSLs and E-NTSLs in tissue mimicking phantom 
For E-LTSLs, as the sample was heated from 25to42°C, US signal intensity progressively 
increased (4–5 fold from 25 to 39.8°C; Fig.3a-b), and at ~40°C a further 2–3 fold 
increase occurred. The inflection point for these changes was computed as~39.5°C, which 
in our model corresponds to the transition temperature of liposomal lysolipids. Likewise, 
E-NTSL contrast also increased from 25–42°C, but the increase was more linear in nature 
(3b). 
3.5 Kinetics of E-LTSLs and E-NTSLs in mouse tumors in vivo 
US images obtained in B mode from time zero to wash out time of liposomes from the 
tumor (~15–30 min) showed significant contrast enhancement in the tumors for both E-
LTSLs (Fig. 4a–d) and E-NTSLs (Fig. 4e–h). In general, maximum contrast enhancement 
was observed for 15–20 min post-liposome injection. Additionally, development of 
contrast with E-NTSLs was more gradual with temperature in comparison to E-LTSLs.  
3.6 Fidelity of motion compensation in mouse tumors 
In the absence of motion compensation in vivo, as time progressed, the contrast variation 
of E-LTSL and E-NTSL was obscured and minimized relative to baseline images (Fig. 
5a–d). When the motion compensation technique was applied for E-LTSLs, a > 2-fold 
drop in standard deviation for mean image intensity occurred, enabling a more robust 
estimate of temporal variations due to state change of liposomes (Fig. 5 e-h, 6a). 
Furthermore, a 6-fold increase in within-ROI signal intensity occurred after injection 
(once the liposomes reached a steady-state temperature greater than their transition 
temperature) vs. background (pre-injection) (Fig. 6b). Similar results were observed for 
E-NTSLs (data not shown). 
3.7 Relationship between motion compensated image intensity and temperature in 
mouse tumors 
Corresponding to our phantom results, following motion compensation, we saw a marked 
increase in peak intensity at 42°C compared to 37°C, which was 2-fold larger than the 
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increase in peak intensity between 39.5°C and 37°C for both E-LTSLs and E-NTSLs 
(Fig. 7). These data were consistent across a cohort of six animals. Interestingly, like in 
vitro tissue mimicking data phantom data, the change in tumor contrast was more 
prominent (~2-fold greater) for E-LTSLs than for E-NTSLs at 42°C. 
3.8. Nanomonitoring of drug delivery in mouse tumors by HPLC 
The heated tumor Dox concentrations were 1.6 ± .04, 1.94 ± 0.35, 1.8 ± 0.06 and 3.8± 0.6 
μg Dox/g tissues for NTSLs, LTSLs, E-NTSLs, and E-LTSLs, respectively (Fig. 8). E-
LTSLs + hyperthermia resulted in a 2-fold greater tissue drug delivery compared to E-
NTSLs +hyperthermia and E-LTSLs alone (p < 0.05, Tukey’s test). Importantly, the level 
of tumor Dox corresponded to the E-LTSL tumor contrast measure for 15 min at 37, and 
42°C, with higher tumor contrast indicating greater drug delivery for E-LTSL samples. 
Such differences were not noted for E-NTSL due to their non-thermosensitive 
characteristics. 
4. Discussion 
MBs can produce up to 15–25 dB in echo intensities of blood flow signals and help better 
determine tortuous angiogenic vasculature than conventional US imaging 25. This is a 
significant advantage, but the degree of contrast enhancement following MB injection is 
rapid and complete, and systemically MBs are degraded quickly after injection 26. To 
circumvent these problems, in this study we encapsulated the US contrast agent PFP in a 
size-controlled manner within liposomes to create long circulating E-LTSLs and E-
NTSLs. The feasibility of incorporating PFP into stealth liposomes in a size-controlled 
manner has been reported previously using lipid-based surfactants (1,2-dihexadecanoyl-
sn-glycero-3-phosphocholine and 1,2-dipalmitoyl-sn-glycero-3-phosphate) to emulsify 
perfluorohexane (PFC6) for loading into liposomes 27,28. Negatively stained liposomes 
synthesized using these surfactants suggested that PFC6 emulsions were effectively 
loaded. Recently, we adapted a method proposed by Ibsen et al. that involves 
incorporation of the water-soluble surfactant 1,3-PD into the aqueous core of the 
liposome to entrap PFP and induce emulsion formation in the liposome 19,24,29. TEM 
conducted following PFP encapsulation suggested that nanoemulsified PFP can be 
successfully encapsulated within the aqueous core at body temperature independent of 
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liposome composition and without impacting the size (~150–200 nm for both E-LTSLs 
and E-NTSLs, Table 1). Interestingly, TEM imaging revealed that at higher temperatures 
(> 40°C), E-LTSLs demonstrate relatively greater membrane relaxation compared to E-
NTSLs (Fig. 2c&f). This is likely due to the presence of lysolipids in the E-LTSLs that 
induce formation of thermodynamically favored micelle-like conformation and lateral 
lipid domains 30. Additionally, the presence of lysolipid impacted the Dox release, with > 
95% drug release for E-LTSLs and < 5% release from E-NTSLs in physiological buffer 
(Fig.1). Importantly, the 1,3-PD method of PFP emulsification in the liposome aqueous 
core provided excellent thermal stability of encapsulated PFP when they transitioned to 
the bubble state at higher temperature, as evidenced by sustained vascular imaging (~15–
20 min) with longer clearance kinetics versus that seen with relevant controls (Fig.4). 
This result is promising, but it is not clear whether the PFP vapors transition back to the 
liquid state when the mouse tumors are cooled down. Additionally, whether the tumor 
accumulated E-LTSLs and E-NTSLs can be used to longitudinally track tumor growth 
needs more investigation in future studies.  
A major challenge of hyperthermia mediated IGDD is the motion of the target (solid 
tumor), particularly in the abdominal region, due to respiration or patient movement. 
Movement impairs precise triggered release of drugs, especially from LTSLs under US 
guidance. In recent years, a variety of techniques to compensate for target motion, 
including increasing the transducer angle increment and using a dual-mode combination 
of the tissue and contrast-MB responses to perform alignment of both tissue and vascular 
structures, have been proposed 31-33. These are promising findings, but the short half-life 
of currently available MBs still prevents their use for IGDD guidance. To assess motion 
correction in an in vivo model and determine the variation of image intensity over time, 
we applied a rigid transformation to the ROIs using our long circulating theranostic 
echogenic liposomes. This procedure maximized the similarity between the ROI in each 
successive frame pair, resulting in a significantly enhanced estimation of temporal 
variation in tumor vascular intensity (Fig 5&6). Thus, we believe that this property 
hypothetically can be used to provide a precise spatiotemporal control of drug release 
from thermosensitive liposomes 34. 
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Clinically, hyperthermia is achieved by using a variety of applicators (e.g., microwave 
applicators, radiofrequency applicators, HIFU) 35. However, these devices and methods 
have drawbacks, including lack of spatial precision and temperature accuracy (e.g., hot or 
cool spots) and inability to achieve controlled mild hyperthermic temperatures (40–
45°C). Previously, we and others showed that MR-thermometry provides high spatial and 
temporal resolution for IGDD of tumors 5,36,37, but MR technology is sensitive to tissue 
motion and to external perturbation of the magnetic field 38. Like MRI, US imaging can 
also determine temperature-based changes in the speed of sound or thermal expansion 
within the mildly heated tissue region by comparing US images frame-by-frame over 
time, but temperature mapping is still problematic due to tissue motion and effects of 
non-thermal and unintended thermal effects on the US signal 39. In the current, we took 
an alternative approach to directly estimate the state of the nanoparticles and thus monitor 
hyperthermia-responsive drug delivery. We mapped the relative intensity variations to the 
temperature-dependent changes in the state of E-LTSLs and E-NTSLs. To do this, we 
relied on changes in acoustic impedance between tissues, fluids, and their surrounding 
microenvironments at various temperatures and transformed these changes into a 
surrogate of relative tissue temperature. Our data show that the motion-corrected US 
intensity of E-LTSLs changes with temperature (Fig. 3a-b). When PFP vaporization 
within E-LTSLs is complete, contrast intensity stabilizes to a fixed level (~37–39°C) and 
then increases at the transition temperature of liposomes (~39.5°C) as the interface 
between liposome and surrounding medium is replaced by multiple interfaces between 
nanobubbles and surrounding fluids. Interestingly, the change in vaporization and US 
intensity was more prominent for E-LTSLs than for E-NTSLs (Fig. 7a-b). We speculate 
that the relative echo obtained for liposomes is a function of PFP vaporization, membrane 
state at higher temperature, and the concentration and agglomeration status of the 
liposomes in blood vessels. E-LTSLs have relatively higher membrane relaxation, and 
this fundamental property may provide stronger echo signals during US imaging at 
relatively greater vascular concentration compared to E-NTSLs at temperatures > 40°C. 
An important utility of such a phenomenon could be in nanomonitoring of drug delivery 
from E-LTSL. As shown in Fig. 8, in the mild hyperthermia ranged (~40-42°C), 
estimations of tumor contrast could reliably predict drug delivery. This discreet 
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prediction and control of drug delivery will likely be negated at temperatures> 45°C due 
to perfusion shutdown, and thus our state-changing echogenic liposomes can serve as an 
excellent surrogate marker of mild hyperthermia in tumors (especially in the absence of 
MR-thermometry). 
Our study has several addressable limitations. First, hyperthermia treatment of tumors 
was performed using the traditional water bath methodology. This method of 
hyperthermia achieves spatially homogeneous heating of selected tissue and controlled 
tumor vascular enhancement, but is not feasible to use clinically for deep seated tumors 7. 
Also, for deep seated tumors this homogeneity may not exist with other types of 
hyperthermia applicators (e.g., HIFU), especially if the treatment cell area (focal spot) is 
smaller than the tumor volume. This has been addressed to some extent through the 
recent development of phased array transducers with appropriate driving electronics that 
enable the creation of a desired focal pattern by making fast temporal displacements of 
multiple foci, thereby significantly enhancing the treatment volume 36. In addition, Bing 
et al. successfully created 3D-printed sector-vortex lenses with annular focal regions that 
enabled customization of the heating volume in rodent models40. Studies are currently 
underway to investigate the contrast variations using sector-vortex lenses with various 
types of animal tumor models to demonstrate this idea in our laboratory. The second 
limitation of this study was reliance on vascular contrast of E-LTSLs and E-NTSLs. 
Given the relatively small size of the liposomes, they may passively accumulate in the 
tumor by the enhanced permeation and retention effect and influence the contrast 
assessment in real time. Our liposomes demonstrate the highest rate of vaporization at 
higher temperature (> 40°C), and a passive accumulation is not expected to dramatically 
alter the imaging feedback at body temperature; in fact, it would help provide a stronger 
signal that may have diagnostic value. Despite this, if tests of the current formulations do 
not meet the proposed criteria, we will adjust the PFP level in the liposomes prior to 
translation into human studies to reduce background artifacts. Third, the temperature 
monitoring by PFP phase-shift in liposomes may not be as precise as the PRFS method 
currently in clinical trials for MRI thermometry. This could impact targeted IGDD, as 
temperatures > 45°C have been shown to shut down tumor vascular perfusion 41. The 
theranostic liposomes proposed in this study is not intended to replace the MR-
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thermometry technology, which has merits for clinical use. We believe that the phase-
changing liposomes may have utility for hyperthermia devices where PRFS cannot be 
applied easily (e.g., Radiofrequency applicators, microwave, ultrasound guided HIFU) or 
for nanomonitoring of drug delivery in tumors with US imaging feedback that is 
currently not possible to achieve with MBs with short-half lives. 
In summary, this work provides important evidence that robust estimation of the state of 
theranostic liposomes and vascular contrast can be obtained from motion compensated 
US images in both tissue mimicking phantom and mouse models of colon cancers using 
temperature induced variations of Laplace pressure. Such elevations in relative image 
contrast correspond to drug delivery. This theranostic technology has the potential to 
guide non-invasive IGDD for tumors that require accurate temporal and spatial 
monitoring of drug treatments. 
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Figure. 1. Release of Dox with temperature as the sample (LTSL, E-LTSL, E-NTSL, and 
NTSL) is heated from 20-43°C at 1°C. Percent release was calculated by assuming 100% 
release with Triton-X, and 0% release at 25°C. 
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Figure. 2. a & d: TEM images of Echogenic thermosensitive (E-LTSL) and non-
thermosensitive (E-NTSL) liposomes showing the spherical liposomes containing PFP-
PD emulsion; (a-c) Gradual and significant relaxation of the E-LTSL membranes due to 
hyperthermia from 37 to 420C; (d-f) E-NTSL from 37-420C showing moderate structural 
changes at 420C 
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Figure. 3. a) Intensity of observed ultrasound image with respect to temperature in the 
range of 31-44°C, b) Fitted curves of the ultrasound image intensity of the liposome as a 
function of temperature by using an evolutionary solver to fit exponential models 
between collected release curve data points. 
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Figure. 4. Enhanced tumor contrast (B-mode) following intravenous injection of 
echogenic liposomes in a mouse model of colon cancer. A sustained increase in tumor 
contrast for E-LTSL and E-NTSL was noted compared to baseline tumor images at 10-
15min. (a)Tumor image prior to E-LTSL injection; (b-d) Enhanced tumor contrast 5, 10, 
15 min post E-LTSL injection respectively; (e) Tumor image prior to E-NTSL injection; 
(f-h) Enhanced tumor contrast at 5, 10, 15 min post E-NTSL injection respectively.  
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Figure. 5. Difference between ultrasound image at a given time and the reference image 
at time t=0s. Values are blue if difference is positive; values are red if difference is 
negative. Intensity values are proportional to difference. 
(a-d) Tumors without motion compensation. As time progresses, difference due to motion 
obscures difference due to nanoparticles (E-LTSL or E-NTSL). 
(e-h) Tumors with motion compensation. Gross motion is compensated allowing intensity 
difference due to nanoparticles to be computed. 
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Figure. 6. (a) A magnified view of average intensity inside the ROI over 100 frames 
(2.35s). Motion compensation reduces the standard deviation by a factor of over 2; (b) 
Mean intensity inside the ROI after motion compensation of observed ultrasound image 
as a function of time. The error bars indicate the standard deviation in the average 
intensity over 100 frames (2.35s) at that time point 
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Figure. 7. Relationship between tumor vascular contrast and temperature from 37- 42°C. 
With increase of temperature, a corresponding increase in tumor intensity was noted 
(maximal signal at 42°C) 
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Figure. 8. a) Doxorubicin concentration determined in tumors post Dox E-LTSL and 
Dox E-NTSL injection.  b) Motion compensated B-mode tumor contrast at 37 and 42°C 
contrast from 0-15min.    
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CHAPTER III 
 
 
CHEMO-IMMUNOTHERAPY WITH FOCUSED ULTRASOUND AND 
SALMONELLA-LADEN THEMPERATURE SENSITIVE LIPOSOMES 
(THERMOBOTS) IN MURINE COLON TUMOR MODEL  
 
Schematic of thermobot and heat-combined chemo-immunotherapy approach 
against colon cancer 
 
1 Earlier version of this chapter has already been published as Ektate, K.; Munteanu, 
M.C.; Ashar, H.; Malayer, J.; Ranjan, A. Chemo-immunotherapy of colon cancer with 
focused ultrasound and Salmonella-laden temperature sensitive liposomes 
(thermobots). Sci. Rep. 2018, 8, 13062.
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Abstract 
Using attenuated Salmonella that efficiently homes in solid tumors, here we developed 
thermobots that can actively transport membrane attached low-temperature sensitive 
liposomes (LTSL) to colon cancer cells for triggered doxorubicin release and 
simultaneous polarization of macrophages to M1 phenotype in combination with high 
intensity focused ultrasound (HIFU) heating (40-42°C). Biocompatibility studies showed 
that the synthesized thermobots were highly efficient in LTSL loading without any 
impact on its viability. Thermobots demonstrated efficient intracellular trafficking, high 
nuclear localization of doxorubicin, and induced pro-inflammatory cytokine expression in 
colon cancer cells in vitro. TB and Image-guided non-invasive HIFU heating applied for 
a total of ~30 min to murine colon tumors enhanced therapeutic efficacy and polarization 
of macrophages to M1 phenotype in vivo. Data suggest that the innovative dual-mode 
thermobots/HIFU modality may improve therapeutic targeting of colon cancer.  
 
Introduction 
Colorectal cancer (CRC) is the second leading cause of cancer-related deaths with an 
incidence rate of 40 % in the United States and an average 5-year survival rate of <15% 
in metastatic disease 1. Chemotherapy of metastatic CRC has modest efficacy and is 
typically associated with significant toxicities. Some recent clinical trials suggest that 
patients with refractive CRC tumors can benefit from the enhancement of the tumor-
immune system interactions 2,34,5. The objective of this study was to combine novel 
thermosensitive liposome-laden Salmonella (Thermobots; TBs) with high intensity 
focused ultrasound (HIFU) heating (~40-42ºC) to determine whether this approach 
influences tumor immunological changes to enhance chemotherapy outcomes. 
 
Attenuated bacterial microorganisms such as Clostridium, Listeria, Salmonella, Shigella 
and Escherichia  coli are known to self-propel and home within a solid tumor as 
tumoricidal agents 6-12. In particular, Salmonella typhimurium (YS1646) demonstrates 
high chemotaxis towards the serine, ribose, and aspartate produced within the benign and 
metastatic tumor core by the quiescent and hypoxic cells7,13,14. Like bacteria, 
conventional liposomes can also accumulate in tumor due to the leaky vasculature15-17. 
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Both liposome and Salmonella provide some levels of tumor clearance, however, each 
modality by itself is insufficient in the killing of tumor cells18. To overcome this barrier, 
we developed TBs by loading Salmonella with low-temperature sensitive liposomes 
(LTSL). LTSLs contains the lyso-pc lipid that undergoes a structural and chemical phase 
change in response to HIFU heating (~42ºC) to achieve triggered drug delivery in tumors 
19-26. HIFU heating also augments the release of heat shock protein antigens to stimulate 
anti-tumor immunity 23,27,28. We posit that the immune effects in the tumor 
microenvironment will be aided further by the simultaneous interactions of the 
Salmonella membrane lipopolysaccharide (LPS) and doxorubicin (Dox) that are known 
pro-inflammatory agents 29. Towards this goal, here we provide insights on the feasibility 
ofTB design principles and chemoimmunomodulatory effects with HIFU heating in 
murine melanoma.  
 
2. Results  
2.1 Salmonella efficiently loads and maintains the therapeutic efficacy of LTSLs. Prior 
research has shown that stealth liposomes passively adsorb on the bacteria membrane by 
electrostatic or Van der Waals type attraction 30. However, the detachment of the 
liposomes from the bacterial membrane in a circulatory environment can be a concern. 
To address this, we synthesized TBs by attaching LTSL onto Salmonella membrane 
using Biotin-Streptavidin chemistry 14,31. Epifluorescence microscopy showed the 
presence of fluorescent Dox (red) overlapped with the rod-shapedSalmonella membranes 
(Fig 1a). SEM confirmed that this likely came from the LTSL as indicated by the 
presence of punctate dots on the bacterial membrane (Fig. 1b). In general, an average of 
15-20 liposomal dots (n=25) were notedon the bacterial membrane. In contrast, 
Salmonella alone appeared smooth. Next, we quantified the Dox loading potential of TBs 
by flow cytometry and fluorescence spectroscopy.A gradual shift in the mean 
fluorescence intensity of TBs in the Dox filter was noted relative to Salmonella alone 
(Fig. 1c). Also, compared to TBs that were passively incubated with LTSLs (TB1; MFI: 
8.16±.014), the shift was significantly higher for Biotin-Streptavidin attached TBs (TB2; 
MFI: 21±0.14; Fig. 1d; see Table 1 for lipid compositions). These observations matched 
with fluorescence spectroscopy measurement that showed ~7.5 times more Dox/bacteria 
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for TB2 (540± 80 ng/ml) compared to TB1 (70± 10 ng/ml) (Fig 1e). Notably, the 
enhanced loading of Dox was not associated with significant changes in the bacterial 
viability between Salmonella and TBs as determined by SYTOX staining (Fig 1f).  
We next characterized the intracellular trafficking and cytotoxicity of TBs. C26 colon 
cancer cells were incubated with Dox, LTSL, TB1, and TB2 in the presence and absence 
of heating (~42°C). Confocal microscopy showed significant nuclear localization of Dox 
in the heated cells. Specifically, 4 h post infection, the uptake and nuclear localization of 
Dox from TBs were significantly higher with 42°C compared to body temperature (Fig 
1i). The increased TB2 uptake and Dox release with heat correlated with enhanced 
therapeutic efficacy (~80% C26 killing) compared to TB alone (~50%). Importantly, 
while the efficacy of TB1 and TB2 was similar at body temperature (~35-40% killing), 
TB2 demonstrated relatively higher potency upon adding heat (~80% killing) compared 
to TB1 (60%), presumably due to enhanced stability of membrane attachment and Dox 
transport inside the colon cell. Based on these data, TB2 (abbreviated as TB) was selected 
for further in vitro and in vivo evaluation. 
 
2.2. TB and heat treatment enhances pro-inflammatory gene expression in vitro. 
LPSendotoxin present in the outer leaflet of Salmonella interacts with immune cells to 
promote the secretion of proinflammatory cytokines, nitric oxide, and eicosanoids 32. 
Whether the LPS immune effects synergizes with TB/heat therapy is not known. Thus, 
the conditioned media from C26 cells that were treated with Dox, LTSL, Salmonella, and 
TB2 in the presence and absence of heat was added to RAW264.7 macrophages, and the 
pro-inflammatory (TNF-α) and anti-inflammatory (IL10) cytokine expression was 
assessed. Heat plus TB treatment significantly enhanced TNF-α in the macrophages 
compared to all treatment groups at 37°C (Fig. 2a). This increase in pro-inflammatory 
cytokine was also accompanied by a decrease in IL10 expression in the heated groups 
compared to controls (Fig. 2b). These results suggest that adding heat to TB or 
Salmonella treatment increases pro-inflammatory properties of colon cancer cells. 
2.3 TBs and HIFU therapy enhances therapeutic efficacy in vivo. The efficacy of 
TB/HIFU was evaluated by tumor growth and histological measurements. Briefly, when 
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the C26 tumors reached >400mm3 volume, the mice were treated with TBs and 
Salmonella (Fig. 3a). 24h post injection, a single non-cytotoxic HIFU treatment (~42°) 
for ~30 min was administered, and tumor volumes were measured for 5days post 
treatment. A pronounced increase in tumor volume (400-500 mm3) was observed for 
HIFU similar to untreated control mice (fig. 3b). In the bacteria treated mice, the tumor 
colonization rates were similar for Salmonella and TBs (Fig.3c). Salmonella-alone 
treatments induced significant tumor volume reduction; however, the effects were not 
impacted by the HIFU treatment. In contrast, the addition of HIFU heating to TB 
treatment resulted in greater suppression of tumor growth rates compared to Salmonella 
or TB alone, likely due to triggered Dox release in colon cells. Next the treated tumors 
were investigated by H&E staining. Mild HIFU heating didn’t induce focal necrosis, 
however a slight increase in the apoptotic bodies was noted. This increase in tumor 
apoptosis with HIFU was not accompanied with a significant increase in the overall 
lymphocyte populations between various treatments groups (Fig. 3d)  
2.4. TB and HIFU treatment alters tumor immune environment towards M1 
phenotype. The mechanisms underlying the in vivo immunomodulatory effects of 
TB/HIFU combination was analyzed in the harvested tumor by flow cytometry. TB/HIFU 
combination caused the highest increase in the expression of M1 macrophages when 
expressed as per gram of tumor compared to all other treatments. HIFU heating also 
enhanced the M1 phenotype in Salmonella alone group; however, this was accompanied 
with a proportional increase in the M2 phenotype. In contrast, TB/HIFU M1 induction 
didn’t result in a compensatory increase in M2 phenotype (Fig. 4a-b). The immune 
microenvironment was also characterized for changes in the influx of either granulocytic 
(Ly6G+) or monocytic (Ly6C+) myeloid-derived suppressor cells (MDSCs) and T-cells. 
The MDSCs, and the general cytotoxic/killer (CD3+, CD8+) T cells and helper (CD3+, 
CD4+) cells and interferon gamma (IFN-γ) expressing CD4+/CD8+ cells/g tumor 
expression didn’t show significant changes at the time of tumor harvest (Fig.  4c-i).  
3. Discussion  
In this study, the feasibility of combining bacteriolytic chemotherapy with TB in 
combination with HIFU heating was assessed. We hypothesized that TBwill 
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simultaneously induce tumoricidal effects, while also aiding in the antitumoral immunity 
with HIFU heating. To enhance in vivo stability, TBs were created by attaching LTSLs 
onto Salmonella membrane actively using Biotin-Streptavidin chemistry 14,31. Biotin-
Streptavidin isamongst the strongest known non-covalent protein-ligand reaction (Ka=2.5 
x 1013M-1) 33,34. This method of cross-linking resulted in a ~7.5 fold greater membrane 
binding of LTSL compared to passive incubation without impacting bacterial viability or 
cellular uptake (Fig. 1c-i). Also, in contrast to some prior reports where Salmonella 
achieved drug deposition mostly in the perinuclear region, TBs with heat achieved 
efficient drug delivery in both the cytoplasm and the nucleus of C26 cells 35. Most likely, 
the heat treatment of cells enhanced membrane fluidity and protein rearrangement in the 
cells aided the Dox transport kinetics molecules 36. An additional unexplored but key 
finding was the initiation of pro-inflammatory phenotype in macrophages following 
exposure to TB/Heat treated 10% conditioned media. 10% condition medium was chosen 
in vitro to mimic in-vivo condition of colon tumors where the peritumoral macrophages 
are likely exposed to such level of tumor-derived cytokines 37. A high expression of TNF-
α, and decreased expression of IL10 was noted in the macrophages. Macrophages and 
dendritic cells are the main producers of TNF-α and their activation typically shifts the 
macrophage phenotype from pro-tumoral M2 to M1 37,38. To explore this premise, we 
assessed M1 and M2 macrophage population in the treated tumors. Both TB and 
TB/HIFU treatment enhanced M1 phenotype compared to all other treatment groups 
(Fig.4), thereby resulting in a relatively enhanced regression of tumor cell in vitro and in 
vivo compared to controls.  
Our study has some limitations. First, while heat treatment decreased IL10 expression in 
vitro, contrastingly an enhanced IL-10 serum protein level expression was observed in 
vivo (Fig. 2, 5). IL-10 is commonly regarded as an immunosuppressive cytokine that 
favors tumor escape from immune surveillance 39. However, there are also some reports 
that suggest that IL-10 inhibits tumor-induced angiogenesis and enhance the production 
of tumor-toxic molecules [e.g., nitric oxide (NO)], especially in lymphoma tumors39. 
While a detailed interplay of cytokines and immune vascularity was not fully 
characterized, we believe that the pro-inflammatory TNFα mediated macrophage 
activation mitigated the IL10 immune suppressive effects to some extent. Studies to 
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delineate the role of IL10 on tumor modulatory pathways especially in the context of 
Doxorubicin, HIFU and Salmonella combinatorial therapy are currently in works. 
Another limitation was lack of significant changes in the T cell and MDSC population in 
the tumors (Fig 4c-i). In particular, the clonal expansion of T-cells is key to resistance 
against recurrence. Although the exact reasons are unclear, late stage growing necrosing 
tumors with reduced presence of patent vasculature (>400 mm3) can decrease the 
infiltration of T-cells form lymph node. To address this, future studies can explore these 
mechanisms further especially by analyzing the T-cell dynamics in draining lymph node, 
and MDSCs in spleen tissue.   
4. Conclusion 
We report for the first time novel thermobots for chemoimmunotherapy with HIFU 
heating. TBs enrich M1 macrophage phenotype and achieve triggered release in tumors 
to enhance therapeutic effects. This technology has the potential for further investigation 
for application in dual-modality therapy settings. 
5. Materials and methods  
5.1 Materials 
The lipids monostearoyl-2-hydroxy-sn-glycero-3-phosphocholine (MSPC), 1, 2-
dipalmitoyl sn-glycero-3-phosphocholine (DPPC), and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy (Polyethylene glycol)2000] (DSPE-mPEG2000 ) 
were obtained from Corden Pharma Corporation (Boulder, CO, USA). DSPE-PEG 
(2000)-Biotin was purchased from NANOCS (NY, USA), and Streptavidin ( 97062-810) 
was bought from VWR (PA, USA). EZ-link NHS-LC-Biotin and trypsin-EDTA, MatTek 
35 mm glass bottom dish with 10 mm glass diameter (NC0445924), SYTOX™ Blue 
dead cell stain (S348557), TRIzol reagent (15596018), and DNase I (EN0525) 
was obtained from Thermo Scientific (MA, USA). iScript™ Reverse Transcription 
Supermix for RT-qPCR (1708840) was purchased from Bio-Rad (CA, USA). 
Doxorubicin (Dox) was acquired from LC Laboratory (MA, USA). The PD-10 column 
was obtained from GE Healthcare Life Sciences, (Buckinghamshire, United Kingdom). 
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Ethylenediaminetetraacetic acid (EDTA) and 4-(2-Hydroxyethyl) piperazine-1-ethane 
sulfonic acid, and N-(2-Hydroxyethyl) piperazine-N′-(2-ethanesulfonic acid) (HEPES) 
were acquired from Sigma (St. Louis, MO). Luria broth (LB) agar and broth were 
purchased from  BD (NJ, USA). Fetal bovine serum was procured from Atlanta 
Biologicals (GA, USA), and Penicillin/ Streptomycin was acquired from Invitrogen (CA, 
USA). Fluorochrome-conjugated anti-mouse monoclonal antibodies were purchased from 
BioLegend (CA, USA: APC-CD11b (101212), PE-CD86 (105008), PE-Ly6C (128008), 
PE-CD4 (100512), APC Cy7-IFNg (505850), Pacific blue-F4/80 (123124), Alexa fluor 
700-CD206 (141734), and BD biosciences: FITC-Ly6G (1A8) (551460). UltraComp 
eBeadswere purchased from Fisher Scientific (Hampton, NH). SYBR green reagent 
(qPCR Master Mix Plus for SYBR green) was purchased from Eurogentec (Liège, 
Belgium). ELISA kits for TNF-α(MTA00B), IL1-β (MLB00C) and IL-10 M1000B were 
purchased from R&D (MN,USA). C26 cells were kindly provided by the National Cancer 
Institute, and RAW 264.7 cells were obtained from ATCC. Salmonella typhimurium 
(YS1646) was purchased from ATCC (Manassas, VA, USA). 
 
5.2 LTSL synthesis and characterization 
LTSLs (lipid composition: DPPC, MSPC, and DSPE-mPEG2000; molar ratio of 
85.3:9.7:5.0) were prepared by hydration of lipid film followed by the extrusion 40. For 
cross-linking to Salmonella membrane, DSPE-PEG2000-biotinlipid was incorporated in 
the LTSL membrane (lipid composition: DPPC, MSPC, DSPE-mPEG2000, and DSPE-
PEG2000-Biotin; the molar ratio of 85.3:9.7:4.0:1). Briefly, lipids were dissolved in 
chloroform, and the solvent was evaporated. The resulting lipid film was hydrated in 
citrate buffer (pH 4.0) at 55 0C for 30 minutes and extruded five times through double 
stacked 200nm polycarbonate filters. Encapsulation of Dox into the liposomes was 
carried out using a pH gradient loading protocol as described by Mayer et al. 41 LTSLs 
were characterized for size (z-average), polydispersity index and zeta potential using 
dynamic light scattering (DLS) with a 90 plus PALS Nanobrook device (Brookhaven 
Instruments, Holtsville, NY, USA). Briefly, 10-20 µl of LTSLs were added to 2 ml of 
PBS in a cuvette, and DLS measurements were recorded at room temperature. An 
average of five measurements was taken, and the mean size and standard deviation were 
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calculated for the LTSLs. For recording the zeta potential, 10 µl of the liposomes were 
suspended in 1500 µl of double distilled water, and an average of 5 measurements was 
taken to record the mean zeta potential.  
5.3 Synthesis of LTSL attached Salmonella (Thermobot or TB) 
Table 1. Cross-linking schemes for Thermobot (TB) 
Thermobot 
(TB) 
Lipid 
Composition 
Diameter± 
SD (nm) 
(LTSL) 
Poly 
dispersity 
Index± 
SD  
(LTSL) 
Zeta 
Potential± 
SD (mv) 
(LTSL) 
Biotin-
Streptavidin 
reaction 
TB1 DPPC, 
MSPC, and 
DSPE-
mPEG2000 
170.41 
±3.1 
0.125 
±0.02 
-27.41 
±4.3 
No 
TB2 DPPC, 
MSPC, 
DSPE-
mPEG2000, 
and DSPE-
PEG2000-
Biotin 
177.67 
±3.3 
0.104 
±0.01 
-34.34 
±13.3 
Yes 
 
A library of LTSL attached Salmonella with active and passive cross-linking schemes as 
given in Table 1 were synthesized 42. For cross-linking, 3 x 108 CFU of Salmonella  was 
suspended in 0.5 ml PBS with 100μg of EZ link NHS-Biotin (dissolved in 5μl DMSO) 
for 45 min at room temperature under mild shaking.Free EZ link NHS-Biotin was 
removed by centrifuging at 3000 x g for 10 min and washing 2 times with PBS.  Cross-
linkingwith LTSL’swas achieved by incubating 3 x 108 CFU of Salmonella with 100μg 
of Streptavidin solubilized in deionized water and 100μl of 22mM Dox loaded LTSL for 
1 h at room temperature. As additional controls, Salmonella was passively co-incubated 
with 100μl of 22mM Dox loaded LTSL for 1h. Unattached liposomes were separated out 
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by centrifuging the bacterial suspension at 3000 x g for 10 minutes. The bacterial pellet 
was washed 2x with PBS and resuspended in 500μl of PBS for further analysis.   
 
5.4 Quantification of Dox in TBs with flow cytometry and spectroscopy 
TBs (n=3; 3 x 108 CFU) were examined in a FACS Aria flow sorter (BD Biosciences, 
Franklin Lakes, NJ, USA) at an excitation wavelength of 488 nm and a 590/30-nm 
emission filter using BD FACS Diva 8.0.1 software. Data were computed and compared 
from the dot plots and histogram plot by counting 10,000 single cell events. 
 
For Dox quantification by fluorescence spectroscopy, TBs (3 x 108 CFU) suspended in 
0.5 ml of PBS was heated in a water bath maintained at 45°C for 30 minutes. The 
bacteria were centrifuged at 3000 x g for 10 min., the supernatant containing the released 
Doxwas collected and the fluorescence was measured at a wavelength of 480/590 nm 
with Spectramax (CA, USA) microplate reader. Concentrations of the Dox in 
supernatants were determined from the linear calibration curve using least squares 
regression method based on the nominal concentration. 
 
5.5 Dox imaging in TB by fluorescence and SEM imaging 
Based on flow and Dox loading, TB2 was selected from 5.4. 200ul of diluted TB was 
added to cover the glass surface of MatTek dish (10 mm glass diameter) for imaging with 
60x oil immersion objective. All imaging was acquired using Olympus ZDC2 IX81 
fluorescence microscope equipped with a color CCD camera, cooled monochrome CCD 
camera, motorized scanning stage, and Metamorph mosaic stitching software. Dox 
fluorescence was collected and measured at a wavelength of 480/590 nm using a 20 ms 
exposure time with a custom made a filter (excitation 480/40 nm, emission 600/60 nm, 
and dichroic 505lp) at 60x APO. 
For SEM, TB2 and control Salmonella wasfixed for 2h in 2.0% glutaraldehyde in 0.2M 
cacodylate at room temperature, rinsed 3x with PBS, and then fixed for 1 hour in 1% 
OsO4 in 0.2M (in water). Fixed samples were then washed 3x with PBS and 20μl of 
fixed TB3 and Salmonella was placed onto a poly-L-lysine coated 12mm glass slide and 
incubated for 30 minutes. The slides were washed with ultrapure deionized water. 
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Samples were dehydrated with increasing content of ethanol for 15 minutes. at each 
concentration (30%, 50%, 70%, 90%, 95% and 100%). A critical point dryer (BAL-TEC 
CPD030), was used to remove ethanol from the dehydrated samples. Samples were 
immediately mounted on stubs with carbon tape and a wafer coated with gold/palladium 
prior to imaging (Cressington Carbon Coater; Balzers Union MED 010 Au/Pt coater). 
High-resolution images were captured with FEI Quanta 600 field emission gun ESEM 
with Evex EDS and HKL EBSD at an accelerating voltage of 20 kV, and a working 
distance of <10mm and the number of nanoparticles attached on the surface of 25 
bacteria was counted manually to determine the average number of nanoparticles 
attached on bacteria.  
 
5. 6 Assessment of TB viability by Flow cytometry 
5 X107 CFU of Salmonella and TB’s was diluted in PBS to achieve a final volume of 1 
ml for viability analysis with SYTOX blue dead cell stain. 1μl of SYTOX blue was added 
to each sample to achieve a final dye concentration of 1μM followed by 5 min. 
incubationin dark at room temperature 43. Salmonella with no treatment and no SYTOX 
blue was used as a control for setting up the flow voltage and gate parameters. Samples 
were analyzed without washing or fixing using a 440/40 nm bandpass filter with BD 
FACS Diva 8.0.1 software. Datawere computed and compared from the dot plots and 
histogram plot by counting 10,000 single cell events. 
 
5.7 Assessment of cellular uptake of TB 
2.5 x 104 C26 cells were seeded in glass bottom Petri dishes overnight and were 
incubated at a multiplicity of infection of 50 with Salmonella, TB1 and TB2 at 37°C or 
42 °C for 1, 4 and 12 h. LTSL (containing 0.02µg of Dox) incubated under similar 
conditions as TB served as a control.Prior to imaging, cells were rinsed with PBS 2x, 
fixed by adding 1ml of 4% paraformaldehyde to the plates for 15-20 minutes at room 
temperature. The nucleus was counterstained with DAPI (3uM) for 10 minutes at room 
temperature and rinsed 2x with PBS. Imaging was performed using Olympus IX81 
confocal microscope with the Doxorubicin filter (ex/em of 480/590) and the DAPI filter 
(ex/em of 365/440) at 40x by randomly selecting multipleregions in the petri dish.  
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5.8 Evaluation of TB cytotoxicity  
Cytotoxicity was assessed for TB at 50 MOI (multiplicity of infection) at 37 and 42⁰C. 
C26 cells (1x105 cells/well) cultured in RPMI 1640 media supplemented with 10% Fetal 
Bovine Serum (FBS) and 1% Penicillin/Streptomycin at 5% CO2 and 37⁰C were seeded 
into 96 well flat bottom plate for 24 h. Cells were washed 2x with PBS to remove 
antibiotic. TBs and Salmonella (50 MOI) suspended in no antibiotic and serum-free 
medium containing 10µM of Dox was added to the culture well and incubated for 4h at 
37 °C and 42°C. Extracellular TB were removed by treating with RPMI containing 
50μg/ml of gentamicin for 1h at 37°C. Next, the culture media was discarded, well were 
washed with PBS and re-suspendedin 100 µL of cell culture media, and incubated at 
37°C for ~20h. An in-vitro homogeneous, colorimetric method for determining the 
number of viable cells using the MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide) was used to determine any cytotoxic effects of the released 
Dox. Briefly, 10μl of 12mM MTT was pipetted into each well, and the plates were 
incubated for 4 hours at 37 °C in a humidified 5% CO2 atmosphere. The absorbance was 
recorded at 540 nm with Spectramax (CA, USA) microplate reader. 
 
5.9 Immune analysis in vitro  
 
5.9.1C26 cell conditioned mediumcollection 
5 x 105 C26 cells /well were treated with 50 MOI of Salmonella, TBs and LTSL 
(containing 50 ng Dox) for 4 h at 37 or 42 °C in RPMI medium (no antibiotic, no serum). 
Extracellular bacteria were removed by treating with gentamicin (50µg/ml) for 1h, and 
cells were cultured for 6h in serum free media. Next, tumor cell conditioned media was 
collected, centrifuged at 1000 rpm for 5 minutes to remove cell debris and the 
supernatant was stored at -80°C.   
 
5.9.2 Treatment of RAW 264.7 macrophages with colon cancer conditioned medium 
0.5 x 106 RAW 264.7 cells suspended in 2mL media were seeded in 24 well culture 
plates overnight. Confluent cells were treated for 24 h with 10% C26 conditioned media 
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from 5.9.1 at 37°C in 5% CO2 incubator. For RNA extraction, media was discarded and 
cells were collected in 1 ml TRIzol reagent and stored at -80°C until RNA extraction was 
performed.  
 
5.9.3 RNA isolation and DNase treatment from RAW 246.7 cells and tumors for 
gene expression analysis 
Total RNA from the RAW 264.7 cells was extracted using TRIZOL according to the 
manufacturer’s instructions. RNA concentration was measured using NanoDrop ND-100 
and 5µg of total RNA was treated with DNase I according to manufacturer’s protocol. 
Post DNase I treatment, the RNA was purified with the phenol-chloroform methodology. 
 
5.9.4 Reverse Transcription Polymerase Chain Reaction (RT-PCR).  
cDNA synthesis was performed using 1µg DNase I treated RNA per reaction using 
iScript Reverse Transcription Supermix for RT-qPCR. Real-Time RT-PCR reaction was 
performed with cDNA diluted 5 x. 
 
5.9.5 Quantitative Real-Time Reverse Transcription Polymerase Chain Reaction 
(qRT-PCR) 
Relative gene expression for IL1β, TNFα (M1 cytokines), and IL10 (M2 specific 
cytokines)was evaluated by qRT-PCR using SYBR green reagent using Applied 
Biosystem 7500 fast Real-Time PCR instrument and indicated specific primers sequences 
(Table 3). qRT-PCR data were analyzed by the 2(-ΔΔCT) method using GAPDH as a 
reference gene.  
Table 2. qRT-PCR primers sequences  
qPCR primers Species Sequences 
mGapdh-forward Mus musculus CATCACTGCCACCCAGAAGACTG 
mGapdh-reverse Mus musculus ATGCCAGTGAGCTTCCCGTTCAG 
mTnf-alpha-forward Mus musculus CACCACCATCAAGGACTCAA 
mTnf-alpha-reverse Mus musculus AGGCAACCTGACCACTCTCC 
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mIl1-beta-forward Mus musculus TGGACCTTCCAGGATGAGGACA 
mIl1-beta-reverse Mus musculus GTTCATCTCGGAGCCTGTAGTG 
mIl10-forward Mus musculus CGGGAAGACAATAACTGCACCC 
mIl10-reverse Mus musculus CGGTTAGCAGTATGTTGTCCAGC 
 
5.10 Evaluation of CD86 and CD206 on RAW 264.7 cells by flow cytometry 
0.5 x 106 RAW 264.7 cells treated with 10% C26 cell conditioned media for 24h were 
imaged at 20x magnification with Olympus ZDC2 IX81 microscope to observe the 
cellular morphology of macrophages. For CD86 and CD206 marker evaluation, cells 
were trypsinized and fixed in 4% paraformaldehyde for 10-15 minute at room 
temperature. Next, cells were washed and re-suspended in 1 ml PBS containing 2% fetal 
bovine serum. 5 x 104 cells were incubated for 30 min with the primary anti CD86-PE 
antibody and primary anti CD206-Alexa Fluor 700 antibody. Isotype corresponding to 
each primary antibody was included as a control. Three washes with 1x PBS containing 
2% FBS were performed, and cells were analyzed by flow cytometry with FACScalibur 
(BD Biosciences). Data were analyzed with FlowJo software v.10.2 (Tree Star Inc, OR, 
USA).  
 
5.11 In vivo study model of colon cancer  
All animal-related procedures were approved and carried out under the regulations and 
guidelines of the Oklahoma State University Animal Care and Use Committee. Female 
10-week Balb/c mice (Charles River, Wilmington, MA) were inoculated with 0.5 x 105 
cells/50μl in the thigh region using a 25-gauge needle (BD, Franklin Lakes, NJ, USA). 
Mice were monitored and tumor growth was measured by serial caliper measurements 
(General Tools Fraction+™, New York, NY, USA). Tumor volumes were calculated 
using the formula (length X width2)/2, where length is the largest dimension and width is 
the smallest dimension perpendicular to the length. When the tumors reached a volume of 
400-500 mm3 mice, were randomized into 6 groups (n=6-7/group). Treatment groups 
were designed as follows: Control+/– HIFU, Salmonella+/– HIFU, TB+/– HIFU. For in 
vivo treatment, 106 Salmonella or TB were administered by intravenous injection, and 
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HIFU was administered 24h later. All mice were sacrificed 5 days after the injection and 
the tumor, liver and spleen and blood were collected for further processing.  
5.12 HIFU hyperthermia treatment set-up and methodology 
For HIFU treatment, mice were anesthetized with 2–5% isoflurane and restrained in 
custom built mouse holders attached to a 3D positioning stage. An integrated ultrasound-
HIFU Alpinion platform with 1.0 MHz central transducer frequency, 45 mm radius, and 
64 mm aperture diameter with a central opening 40 mm in diameter was used for tumor 
identification and treatment. The mouse was oriented so that its dorsal side was facing the 
transducer and the caudal half was lowered into a 37 ºC water bath.  The path from the 
transducer to the tumor was aligned along the z-axis. The center of the tumor was aligned 
with the HIFU focus at a fixed focal depth for efficient coverage, and VIFU-2000 
software was used to define the target boundary and slice distance in X, Y, and Z 
directions for automatic rastering of the transducer as demonstrated previously 44. HIFU 
treatment parameters used were as follows: 35% duty cycle, 5Hz PRF, and 6W Power to 
achieve a mean target temperature of 40–42.5 ºC at the focus. A 3 x 3 raster pattern was 
followed for hyperthermia treatment of tumors with HIFU. The distance between any two 
central focus points on a tumor was 2 mm to ensure that the entire volume was heated to 
~42 ºC. Each point (1 x 1 x 10 mm) within the raster pattern was heated 60 s. The total 
treatment duration was ~30 min. to cover the entire tumor.   
5.13 Post-treatment tissue analysis 
Upon completion of treatment, mice were euthanized. Tumor and tissue samples from 
liver, spleen blood were collected for flow cytometry, qPCR and ELISA. Tumor and 
serum samples for qPCR and ELISA were snap-frozen over liquid nitrogen, and stored at 
−80 °C until analysis. 
5.14 Flow cytometric analysis  
Tumor tissues were minced and digested in 200 U/ml collagenase IV buffer  at 370C for 
1.5 hours. The digested tissue was strained using a 70μm cell strainer (Corning Inc., 
Corning, NY) to obtain single cell suspensions. Cells were stained using antibody mixes, 
for different immune cell populations, prepared in 1X PBS with 2% FBS staining buffer, 
incubated for 1 hour at 40C in dark. For IFNγ detection, staining buffer contained 0.1% 
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saponin was used for permeabilization. The labeled cells were then fixed in 4% 
paraformaldehyde and analyzed using FACS Aria flow sorter (BD Biosciences, NJ) using 
the following panel - M1 macrophages (CD11b+ F4/80+ CD86+), M2 macrophages 
(CD11b+ F4/80+ CD206+), myeloid-derived suppressor cells (MDSCs)- granulocytic 
(CD11b+ Ly6G+ Ly6C-) and monocytic (CD11b+ Ly6G- Ly6C+), and T cells (CD3+ 
CD4+ CD8+ IFNγ). UltraComp eBeads were used for compensation controls as per the 
manufacturer’s instructions. Fluorescence-minus-one (FMO) samples were used as 
negative controls. Data was analyzed using FlowJo software v.10.2 (Tree Star Inc, OR, 
USA). Data is expressed expressed as cell number per g of tumor using the formula 
N = NSxNT/NAxW, where NS is cells of interest, NA - number of cells counted in flow 
cytometer (singlet tumor cells), and NT as tumor cells = 20000, W – weight of tumor.  
 
5.15 Determination of serum cytokine levels by ELISA  
IL1β, TNFα and IL10 protein levels were measured in the serum by enzyme linked 
immunosorbent assay (R&D Inc., MN, USA – Quantikine ELISA), according to the 
manufacturer’s instructions. For serum separation, the whole blood was collected and 
allowed to clot at room temperature for 30 minutes. The clot was removed by 
centrifugation at 6000xg for 20 minutes, at 4°C. The serum was transferred into a new 
polypropylene tube and stored at -80°C until used for ELISA cytokine analysis. 
 
5.16 Bacteria quantification 
Aseptically collected tumors were individually placed in a pre-weighed sterile tube 
containing 500μl of cold sterile PBS and placed on ice. Briefly, all tumor samples were 
homogenized and serially diluted with PBS and plated on LB agar plates. The colonies 
were enumerated and expressed as CFU per gram of tumor.  
 
5.17 Statistical Analysis  
The relative gene expression from real time quantitative PCR analysis was conducted 
with comparative CT method (2
-ΔΔCT) using GAPDH as a reference gene. Mean values for 
conditioned media treatment were compared to control with one way ANOVA and 
Tukey's multiple comparisonspost-hoc test. 
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Values were reported as a mean ± standard error of the mean (SEM) and the number of 
independent replicates is indicated in the figure legends. Treatment groups were 
compared for differences in mean using analysis of variance (ANOVA) followed by 
Tukey's multiple comparisons posthoc test. All analyses were performed using GraphPad 
Prism 7.0 (GraphPad Software Inc.). All p-values were two-sided, and p < 0.05 was taken 
to indicate statistical significance.  
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Fig. 1: In-vitro characterization of thermobots. a) Fluorescence microscopy showed 
LTSL presence on the Salmonella as indicated by red fluorescence of Dox. Salmonella 
(not shown) was used as control and didn’t demonstrate any fluorescence. All images 
were captured with the 60x oil immersion objective lens; b) SEM image  of Salmonella 
showed punctate liposomal dots on the membrane; c) Histogram plots indicated a gradual 
increase in the MFI for bacterial population positive for dox (depicted in blue) compared 
to the control (depicted as red peak); d) Dox quantification by spectroscopy and flow 
cytometry demonstrated 2-4fold greater Dox loading with streptavidin-biotin crosslinking 
for TB2 compared to TB1 (p<0.0001); e-f) Viability of TB post crosslinking determined 
with SYTOX blue show no major shift in the dead cell population)fluorescence for TB’s 
from controls in the FACS density plot; h)  Cellular viability of C26 cells post treatment 
with dox, LTSL and TBs suggested enhanced bacterial killing at  42°C compared to 37 
°C. Streptavidin-biotin cross linking improved intracellular Dox delivery from TB2 
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compared to TB1. Data normalized to control samples at 37°C. Values represent mean± 
SE (n=6); i) C26 cells were efficiently infected by Salmonella, and achieved efficient 
intracellular Dox delivery at 4 h post infection with heat. Confocal images were captured 
at 40x magnification. Dox was shown in red and nuclei in blue 
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Figure 2: Impact of TB/heat treated C26 condition media on RAW264.5 macrophage 
cytokine gene by qRT-PCR. a) TB2/42°C achieved significantly higher TNF-α gene 
expression compared to controls, dox and LTSL treatment at 37°C and 42°C; b) 
Significant drop in IL1-β expression at 42°C compared to body temperature was noted 
for all treatments. Values represent means ± SE (n = 3) for each treatment, #,*p < 0.05 
 
 
 
 
 
*p<0.05 
a. b
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Figure 3: In vivo efficacy in C26 colon tumor model following HIFU/TB treatment. 
a) Female Balb/c mice (N=6/group) were inoculated with 0.5*10
6
 C26 cells 
subcutaneously in the upper thigh region. When the tumors reached a volume of 
>400mm
3
 mice, were injected with a single dose of saline/Salmonella/TB followed by 
HIFU treatment for 30 mins 24h post injection. Mice were sacrificed on day 5 and the 
organs were processed; b) Tumor volume over the 5-day treatment duration suggested 
significant tumor regression in the treated groups. TB/HIFU demonstrated highest 
HIFU+ HIFU
Apoptotic 
bodies 
b
c
a
*p < 0.05 
d.  
Apoptotic 
bodies 
88 
 
efficacy compared to other groups; c) Colony forming unit (CFU) per gram of tumor 
enumerated by plating tumor homogenates on LB agar suggested efficient tumor 
colonization with TB with and without HIFU; d) H&E sections of mice tumors suggested 
an increase in the apoptotic bodies for HIFU+ tumors in comparison untreated tumors. 
Values represent means ± SE for each treatment; *p < 0.05 from control (ANOVA 
followed by Tukey’s) 
 
 
 
 
 
 
  
89 
 
 
 
Figure 4: Evaluation of infiltration of immune cells in colon tumors by flow 
cytometry. Tumor cells were labelled ex vivo with following panels: macrophages 
(CD11b+, CD86+/CD206+), MDSC’s (CD11b+, Ly6C+/Ly6G+) and T cells (CD3+, 
CD4+/CD8+, IFN-γ+). A significant enhancement in M1 macrophage for TB/HIFU was 
noted. Values represent means ± SEM (n = 6) for each treatment *p < 0.001 
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Fig 5: Enhanced levels of pro-inflammatory cytokines in serum in response to TB 
treatment. ELISA was performed to detect the serum cytokine levels of TNF-α, IL1-β 
and IL-10; a) TB2 + HIFU achieved highest TNF-α serum cytokine level, significantly 
different from control, Salmonella and TB treatment at body temperature and HIFU 
heating; b) IL-1β serum cytokine levels suggested 2-3 fold increase in response to TB 
treatment compared to controls; c) IL-10 increased for TB±HIFU in comparison to 
controls. Values represent means ± SEM (n =4) for each treatment *p < 0.05 
 
 
 
 
 
 
 
 
 
 
 
*p < 0.05 
 
a b c
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CHAPTER IV 
 
 
MAGNETIC BACTERIA BOUND THERMOSENSITIVE LIPOSOMES FOR 
CELLULAR DELIVERY OF DOXORUBICIN IN MURINE COLON TUMOR 
MODEL WITH HALBACH ARRAY 
 
Abstract 
Low-Temperature sensitive liposomes (LTSLs) release doxorubicin in tumor blood 
vessels with hyperthermia (~40-45⁰C), but its therapeutic efficacies can be limited by a 
short half-life (<1h) and poor extravasation in the tumor tissues. Objectives of this study 
were to 1) Synthesize Magnetospirillum magneticum (AMB-1) conjugated LTSL (AMB-
LTSL) 2) determine doxorubicin delivery and cell killing in-vitro with AMB-LTSL and 
3) Utilize Halbach array to localize AMB-LTSL in mice colon tumors. AMB-LTSL 
generated by biotin-streptavidin affinity reaction was assessed for binding efficiencies, 
cellular uptake, and viability by flow cytometry, confocal microscopy, and cytotoxicity 
assays. Localization of AMB-LTSL in murine colon tumors following intravenous 
injection with Halbach array was assessed by histopathology, fluorescence imaging, and 
bacterial colony culture.  Results indicated that biotin-streptavidin affinity reaction 
achieved > 90% binding of LTSLs on AMB membrane. < 5% doxorubicin was released 
from the LTSL at body temperature (37°), while > 95% was released at ~42ºC. 
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AMB-LTSLs were viable and enabled efficient intracellular doxorubicin delivery 
compared to LTSL alone.  In addition, the Halbach focusing for 1h enhanced AMB-1 
localization in the murine colon tumor. Our initial data suggest that AMB-LTSL can aid 
doxorubicin therapy of colon cancer with magnetic guidance. 
 
Introduction  
Low-Temperature sensitive liposomes (LTSLs) are currently in clinical trials for the 
treatment of hepatocellular carcinoma and liver tumors in combination with Radio 
frequency ablation (RFA) and focused ultrasound 1-3. LTSLs mediated intravascular 
content release has been found to enhance targeted doxorubicin therapy of solid tumors4. 
Although superior to conventional liposomes, LTSL currently have a short half-life,  and 
demonstrate poor extravasation in tumors5,6. Since solid tumors (e.g. colorectal, 
pancreatic and breast cancer) in advanced stages lack vascular network and functional 
lymphatics in the tumor core, the intravascular nature of LTSL delivery can impact 
homogeneous therapy in such cases7,8. Thus, modulation of the extracellular matrix of 
solid tumors with newer approaches is an unmet need 9,10. One approach to address this 
can be by the development of dual-mode bacterial carriers that target hypoxic tumor 
cores11,12. We propose that the magnetic bacteria Magnetospirillum magneticum (AMB-
1) attached LTSLs can achieve delivery of LTSLs to tumor core with a magnetic focusing 
device (e.g. Halbach array). 
AMB-1 is flagellated gram-negative, magnetic, aquatic bacteria that can colonize murine 
tumors13,14. AMB-1 also contains magnetite (Fe3O4) particles that allow them to align 
along the geomagnetic field of the earth 15, 16. It is currently believed that AMB-1 prefer 
low oxygen (hypoxic) conditions for optimal growth and reproduction17, and in the 
presence of the local magnetic field can propel with an average swimming speed of 
49μm/s (25-50 body cell lengths/s) 18. The AMB-1 membrane is rich in amines and can 
be covalently linked to therapeutics19. Thus, if LTSL can be attached to the AMB-1 
membrane and are guided using an external magnetic navigation system such as Halbach 
array, it is possible to achieve intratumoral drug release.  
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Halbach array is a special arrangement of permanent magnets that augments the magnetic 
field on one side of the array while canceling the field to near zero on the other side 20. It 
was invented in the 1980s by Physicist Klaus Halbach at the Lawrence Berkeley National 
Laboratory21. Halbach array creates a strong pull and push force within the magnetic field 
8,22 . Halbach array pulls the magnetic nanoparticles within the tumors against the blood 
flow whereas the push properties direct particles to a precise location 23,24.  Although 
prior research that used permanent magnets or electromagnets for magnetic localization 
of nanoparticle, drug and/or gene delivery to tumors/diseased location were somewhat 
successful, they were limited by the sharp fall in the magnetic field at the depth of 
tumors/lesion, limiting localizations and therapeutic outcomes 25,26. For example, current 
0.2-.8T magnetic devices achieve a maximum focusing depth of 5-12 cm in animal and 
human models with 100-500nm particles2728. However, the targeting of magnetic 
particles to deep-seated/ larger solid tumors in the tumor core requires a much stronger 
magnetic field at the depth of the tumor. We hypothesize that the strong magnetic field at 
depth created by Halbach array will help enhance localization of magnetic particles, 
maximizing delivery of therapeutics at the targeted regions22. If successful, AMB-1 will 
also address the current limitations of microbe based navigational limitation through a 
guided approach in the systemic circulation 29,30. AMB-1 does not induce a systemic 
immune response, and thus high dosage administration of the bacteria can be performed 
in patients without adverse effects 11. Furthermore, AMB-1 can be imaged with MRI for 
the correlation between drug delivery and treatment outcomes. Thus, our proposed 
objectives of creating AMB-1-LTSL with Halbach focusing stems should increase the 
overall therapeutic index. Here, we covalently attached AMB-1 membrane amines with 
LTSL19, assessed feasibility of AMB-LTSL navigation propulsion with external Halbach 
guidance, drug delivery, and imageable features in vitro and in murine xenograft tumor 
models. Data suggest that AMB-LTSL synergistically enhance colon cancer cell death 
and targeted drug release from LTSL with mild hyperthermia. 
Materials and methods  
2.1 Materials 
Monostearoyl-2-hydroxy-sn-glycero-3-phosphocholine (MSPC), 1,2-dipalmitoylsn-
glycero-3-phosphocholine (DPPC), and 1,2-distearoyl-sn-glycero-3-
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phosphoethanolamine-N-[methoxy (Polyethylene glycol)2000] (DSPE-mPEG2000 ) 
were obtained from Corden Pharma Corporation (Boulder, CO, USA). DSPE-PEG 
(2000)-Biotin (NANOCS), Streptavidin (VWR), EZ-link NHS-LC-Biotin (Thermo 
Scientific), Chloroform, Citrate buffer 300mM, and Dox was obtained from LC 
Laboratory (Woburn, MA, USA). Modified magnetic growth media (MSGM) and  
MSGM agar plates with 0.7% agar with hypoxia jar were obtained from Oxoid. The PD-
10 column was obtained from GE Healthcare Life Sciences, (Buckinghamshire, United 
Kingdom, UK). C26 cells were kindly provided by the National Cancer Institute, and 
Halbach array was built by Dr. Piao. 
 
2.2 Bacterial culture  
AMB-1  was cultured in modified Magnetospirillum growth medium (MSGM) at 30°C in 
sealed tubes with <5 % headspace till a brown pellet was observed at the bottom of the 
tube (5-6 days)31.  
 
 2.3 LTSL synthesis 
LTSLs with lipid ratio combinations (lipid composition: DPPC, MSPC, DSPE-PEG2000 
and DSPE-PEG2000-Biotin molar ratio of 85.3:9.7:4:1 were prepared by hydration of 
lipid film followed by the extrusion method32. Briefly, lipid mixtures dissolved in 
chloroform was evaporated and the resulting lipid film was hydrated in citrate buffer (pH 
4.0) at 550C for 30 min and extruded five times through double stacked 200nm 
polycarbonate filters to yield a final lipid concentration of 50mg lipid/ml. Encapsulation 
of doxorubicin (Dox) into the LTSLs was carried out using a pH-gradient loading 
protocol as described by Mayer et al. 33. To do so, the pH LTSL solution was adjusted (by 
column) to 7.4 using PBS, whereas the aqueous core remained acidic at pH 4. Dox was 
loaded at 2 mg per 100 mg lipid concentration at 37 °C for 1h. Free Dox was removed 
using a PD-10 size-exclusion column equilibrated with 5–10 column volumes of 1x 
phosphate buffer saline (PBS).  
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2.4 Characterization of LTSL  
LTSLs were characterized for size (z-average) using dynamic light scattering (DLS) with 
90 plus PALS Nanobrook (Brookhaven Instruments, Holtsville, NY). Briefly, 10-20µl of 
LTSL were added to 2 ml of PBS in a cuvette and DLS measurements were recorded at 
room temperature. For each liposomal formulation, an average of 5 measurements was 
taken and the mean size and standard deviation were calculated for the biotin-LTSL. 
2.5 Synthesis of AMB-LTSL  
AMB-LTSL was prepared with biotin and streptavidin chemistry. Briefly, the surface of 
the AMB-1 was modified with biotin and subsequently linked to LTSL’s with terminal 
biotin functional group with streptavidin intermediate molecule. 0.5 ml of AMB-1 at an 
OD470 of 2 was co-incubated with 100μg of EZ-Link NHS Biotin (ThermoFisher 
Scientific) for 45 minutes at room temperature with mild shaking. Unreacted EZ-Link 
Biotin was removed by centrifuging at 4000x g for 20 minutes and washed 2x times with 
PBS. One pot-click reaction for crosslinking LTSL to AMB was carried out by 
incubating AMB-1 with terminal biotin with 100μg of Streptavidin and 100μl of 22mM 
Doxorubicin loaded LTSL for 1h at room temperature. Unattached liposomes were 
separated out by centrifugation at 4000x g for 20 min. The AMB-LTSL pellet was 
washed 2x times to remove residual unattached liposomes and suspended in RPMI1640 
(No FBS and Penicillin-Streptomycin) or further experiments. To record the size, 10-20µl 
of the AMB-LTSL sample was added to 2 ml of PBS in a cuvette and DLS measurements 
were recorded at room temperature. An average of 5 measurements was taken, and the 
mean size and standard deviation were calculated. 
2.6 In vitro assessment of Magnetic Behavior of AMB-LTSL complexes 
 AMB-LTSLs were placed in an array of magnets made-up of 5 permanent magnets 
placed in a circle with the focus of the magnetic field in the center. 1.5 ml Eppendorf 
tubes with the complexes were placed in the hollow of the magnet array for 30 min, and 
the magnetotaxis in the tubes was characterized.  
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2.7 Quantification of LTSL on AMB-LTSL by flow cytometry and spectroscopy 
AMB-1 and AMB-LTSL (n=3; 3 x 108 CFU) were examined in a FACS Aria flow sorter 
(BD Biosciences, Franklin Lakes, NJ, USA) 34 at an excitation wavelength of 488 nm and 
a 590/30-nm emission filter using BD FACS Diva 8.0.1 software. Data was computed 
and compared from the dot plots and histogram plot by counting 10,000 single cell 
events.  For determining the amount of Dox positive LTSL on the AMBs, 0.5 ml of 
AMB-LTSL and AMB (same OD470 as AMB-LTSL) suspended in PBS were heated in a 
water-bath maintained at 45°C for 30 minutes. The bacteria were pelleted at 2000xg for 
10 minutes, and the supernatant with the released dox was collected for fluorescence 
measurements. AMB-1 was used as a control for the drug estimation studies of AMB-
LTSL. 
 
2.8 Assessment of viability of AMB-LTSL  
The viability of the AMB-1 pre and post-crosslinking of LTSL was determined by 
staining the cells with SYTOX blue. 1ul of SYTOX blue (1uM) was added to 5x107 
bacterial cells/ml, incubated for 5 min in dark for viability assessments. Samples were 
protected from light, and the staining procedure was not allowed to proceed for longer 
than 30 min. Samples were analyzed with flow cytometry without fixing using a BV421 
(440/40 nm) band pass laser. 
2.9 Evaluation of cellular toxicity of AMB-LTSL at mild hyperthermia 
C26 colon cancer cells cultured in RPMI 1640 media supplemented with 10% Fetal 
Bovine Serum (FBS) and 1% Penicillin/Streptomycin were harvested using trypsin-
EDTA (Gibco). For cytotoxicity assessment, C26 cells seeded at the cellular density of 
1x 105 cells/well in 96 well flat bottom plate were incubated overnight to allow adhesion 
to the plate. Non-adherent cells were removed by washing with media (No FBS and 
Penicillin-Streptomycin). 5μM concentrations of Dox, Dox-LTSL, AMB-1 (OD470= 4) 
and AMB-LTSL (5μM Dox) was added at 37 and 42 °C. For hyperthermia treatment, 
samples were incubated for 4h in a CO2 incubator at 42°C. Post-treatment, the wells were 
treated with RPMI containing 50μg/ml of Gentamicin for 1h to kill extracellular bacteria 
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and additional incubation for ~20h at 37°Cwas performed. For the non-hyperthermia 
(37°C) group, cells were treated for 1h followed by treatment with RPMI containing 
50μg/ml gentamicin for 1h. Following gentamicin treatment, cells were washed and 
incubated for an additional 22h before performing MTT. 
For MTT, 10μl of 12mM MTT reagent was added to the treated cells for 3h and 
incubated at 37°C. MTT reagent was also added to empty wells with media as blank 
control.  Next, all but 25μl of media was removed from the well, and 50μl of DMSO was 
added to assess formazan products spectrophotometrically at 540nm. Cells viability was 
calculated by normalizing absorbance values obtained from untreated C26 cells.  
2.10 In vivo assessment of AMB-LTSL targeting in murine colon cancer  
All animal-related procedures were approved and carried out under the regulations and 
guidelines of the Oklahoma State University Animal Care and Use Committee (VM 16-
4). C26 cells were cultured at 80–90% confluence in RPMI supplemented with 10% v/v 
fetal bovine serum (FBS) and 1% v/v streptomycin/penicillin. Female  Balb/c mice 
(~10wk old, Charles River, Wilmington, MA) were inoculated with 0.5 x 106 C26 cells 
suspended in 50μl PBS of cells in the thigh region of the mouse hind leg using a 25-
gauge needle (BD, Franklin Lakes, NJ, USA). Mice were monitored for tumor growth by 
serial caliper measurements (General Tools Fraction+™, New York, NY, USA). Tumor 
volumes were calculated using the formula (length x width2)/2, where length is the largest 
dimension and width is the smallest dimension perpendicular to the length.  
Mice with tumor volume of 400-500 mm3 were assigned to the following treatment 
groups: control, AMB-1 (± Halbach array), AMB-LTSL (± Halbach array). 1.5 x 109 
AMB-1 and AMB-LTSL (23.5µM of Dox) were administered by intravenous injection, 
and the tumor bearing mice were placed in the Halbach array system for 1h under gas 
anesthesia (Figure 4a.). Mice were sacrificed 2h post-injection of AMB and AMB-LTSL, 
and the tumor, liver, spleen and blood were collected for endpoint assessments.  
2.11 Evaluation of Colony forming units (CFU) of AMBs in colon tumors 
Tumors (n=3) were homogenized with zirconia beads using Mini-Beadbeater-16 
(Biospec Products Inc., OK, USA) at 3450 oscillations/min (four cycles of 30 seconds) in 
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a 7mL polypropylene screw-cap micro-vials (1mm diameter, Biospec Products Inc., OK, 
USA). 500ul of tumor homogenate suspended in 4.5 ml of warmed Magnetospirillum 
growth medium (MSGM) with 0.7% agar was serially diluted, and 10µl of diluted 
suspension (n=5) was plated on the MSGM plates. The plates were incubated in a 
hypoxia oxoid jar or in zip-locked bags at 30°C periodically flushed with N2 gas for 3-7 
days to allow bacterial replication.  
2.13 Prussian blue staining of AMB-LTSL treated tumor sections 
Tumor sections (8µm) were de-paraffinized and hydrated in distilled water with 2 
changes of xylene each for 10 minutes. Rehydration was performed 2x each for 5min 
with 100% ethanol, and 2min each with 95% and 70% ethanol. Next, the sections were 
rinsed with water and dipped in hydrochloric acid and potassium ferrocyanide (prepared 
immediately before use) mixed in equal parts for 20 min. Finally, the slide containing the 
tissue sections were washed 3x with distilled water and counter-stained with DAPI 
nuclear staining, dried and cover-slipped with a resinous mounting medium for imaging 
using an Aperio scan scope at 20x.   
2.14 Fluorescence imaging to detect doxorubicin in tissue sections 
Whole tumor tissue sample (n=2) collected from AMB-LTSL± Halbach injected mice 
were analyzed for Dox distribution. Two 8µm formalin fixed and paraffin embedded 
tumor sections were mounted per slide using DAPI containing medium (Vector 
Laboratories). Imaging was performed at an exposure time of 10 ms (ex/em of 365/440) 
to visualize cell nuclei, and Dox was imaged at an exposure 100 ms (ex/em of 480/590). 
Image acquisition and display parameters were constant for treatment groups for 
qualitative comparison. Whole-section digital images were acquired using a 10X 
objective on an Olympus ZDC2IX81 fluorescence microscope equipped with a color 
CCD camera, cooled monochrome CCD camera, and motorized scanning stage.  
2.15 Tumor MRI imaging of AMB-LTSL 
The optical density of AMB-1 suspended in 3% gelatin in 1.5 ml Eppendorf tubes was 
measured at 600nm. Next, the tubes were aligned in a plastic box, and the box was 
subsequently filled with 0.7% agar. The boxes were kept at 4°C to solidify gelatin for 
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maintenance of homogenous distribution of bacteria. For in vivo studies, mice injected 
with AMB-1 and exposed to Halbach arrays were sacrificed and frozen at -20°C until 
MRI imaging. MRI imaging was performed on a 7-Tesla MRI scanner (Bruker BioSpin, 
Ettlingen, Germany) using the T1gradient echo sequence ( te= 1300 ms and tr = 9 ms), 
and T2 sequence ( te= 2500 ms and tr = 33 ms). Single slice images were acquired in all 
planes (axial, sagittal and coronal). The slice position for the cine also utilized the same 
sequence. For cine and volume imaging, a field of view (FOV) of 3.5 × 3.5 cm was 
chosen and 256 phase encode and read steps were used to resolve the spatial distribution 
of excited spins.  
2.16 Statistical Analysis  
Treatment groups were compared for differences in means for cell viability assay, 
bacterial viability determination using analysis of variance (ANOVA) followed by 
Tukey's multiple comparison test. Dox quantification amongst groups and Colony 
forming unit (CFU) ± Halbach treatments were compared with unpaired t-test. All 
analyses were performed using GraphPad Prism 5.0 (GraphPad Software Inc.). All p-
values were two-sided, and p < 0.05 was taken to indicate statistical significance. Values 
were reported as the mean ± standard error of the mean (SEM). 
3. Result  
3.1 Characterization of LTSL  
The hydrodynamic diameter and polydispersity index of biotin containing LTSL at room 
temperature (~25⁰C) value is shown in Table 1. LTSLs were between 170-190nm with a 
polydispersity index of ~0.2, and showed a zeta potential of -38.7±2.8 (Table 1).   
Table 1. Size, polydispersity index, and zeta potential of biotin functionalized LTSL   
Liposome Diameter ± SD Poly dispersity Index ± 
SD 
Zeta Potential ± SD 
LTSL  
(1% Bitoin) 
172.765 ± 3.44 0.189 ± 0.0222 -38.7 ± 2.7474 
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3.2 Synthesis and characterization of AMB-LTSL complex  
LTSL attachment to AMB-1 didn’t result in a significant loss in bacterial viability 
(Fig.1b). The EZ-Link-NHS biotin35 conjugated schematic of LTSL-biotin functional 
groups with streptavidin molecule containing 4 binding sites per molecule is shown in 
Figure 1a). These AMB-LTSL showed efficient magnetotaxis in the center of 
sphericalHalbach array within 10-30 min (Figure 3a).  
Dox emission from AMB-LTSL was evident at 480-590 nm in confocal imaging (Figure 
2g.). DLS showed that the size of AMB-1 (448.40 nm) doubled upon complexation of 
LTSL to AMBs (766.65nm) (Figure2a). The peak side scatter fluorescence moved 
towards the right under flow cytometry (Figure 2b, c). The autofluorescence of AMB-1 
was adjusted to reduce false positives to a minimum and used as a reference gate to test 
AMB-LTSL. >90% of AMB-LTSL was positive for the Dox signal (Figure 3e). In 
contrast to this, AMB-1 co-incubated with LTSL attached < 25% of LTSLs (Figure 3e.). 
The binding was also evident in spectroscopic measurements with a 3 fold higher levels 
of Dox/ml for AMB-LTSL detected in comparison to the AMB-1 and LTSL passive co-
incubation (Figure 3f).   
3.3. Evaluation of AMB-LTSL viability by flow cytometry 
SYTOX™ Blue is a high-affinity nucleic acid stain that penetrates cells with 
compromised plasma membranes. Sytox staining for AMB-1 and cross-linked with 
FACS did not indicate significant changes in the. In general, a 2-4% reduction in viability 
of crosslinked AMB-LTSL was noted over time (Figure 3b.).  
3.4. Efficacy of AMB-LTSL against colon cancer cell with mild hyperthermia 
LTSL-Dox and AMB-1 reduced the viability of C26 colon cells by ~20% and ~47% 
compared to untreated control at 37°C (Figure 3h). Adding heat (42°C) to AMB-LTSL 
reduced the C26 viability by ~ 70% compared to AMB-1 likely due to Dox release from 
LTSLs36.  
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3.5 Halbach array enhanced AMB-1 and AMB-LTSL localization in colon tumors 
Mice injected with AMB-1 and AMB-LTSL were placed on the Halbach array platform 
for 1 h with the tumor in close proximity to the magnets (Figure 4a). Tumors assessed for 
AMB-1 population suggested a 5-log increase in CFU with Halbach focusing relative to 
controls (n=3). Also, the spleen and liver tissues showed a ~50 and ~5 log CFU reduction 
in the AMB-1 colonies for Halbach focused groups compared to non-focused mice 
(Figure 4 f, g.). MRI imaging performed to correlate with the CFU in the organ did not 
demonstrate contrast enhancement for Halbach focused AMB-1s related to untreated 
controls (Figure 6 b). The population of AMB-1 was evident in the tumor sections in the 
presence and absence of Halbach array (Figure 4c, d).AMB-1 associated iron oxide was 
mainly detected along the connective tissue septa or in perivascular locations of tumors 
37. The Prussian blue staining indicated a higher population of tissue macrophages around 
AMB-1 injected mice relative to AMB-LTSL; reasons of which will need to be 
investigated in future studies. In general, histological analysis suggests that the Halbach 
focusing did not impact the migration of AMB-LTSL relative to unfocused bacteria at the 
time-point tested (Figure 4 b, c, d). This was also evident in fluorescence imaging where 
a significant enhancement in the dox fluorescence for magnet focused vs. unfocused 
AMB-LTSL mice was not observed (Figure5).  
4. Discussion  
Homogeneous drug delivery to tumors with nanoparticle is an area of active research 
investigation13,38. But, the reliance of nanoparticles on systemic circulation and the 
absence of a self-propelling system that can drive therapeutic to tumors can severely limit 
these processes39,40. Intravascular delivery of drug from LTSL are slightly better, but as a 
vascular drug delivery systems,  their reach in deeper regions of the tumor is still 
limited41. In this study, the ability of AMB-LTSL for magnetically guided delivery of 
doxorubicin in the tumor was investigated. AMB-LTSL cross-linking was performed 
with biotin-streptavidin non-covalent chemistry that has a high association constant 
(Ka=2.5 x 1013M-1)42. This chemistry was easy to perform and demonstrated reproducible 
and high LTSL coupling efficiencies (~90%; Figure 2e) 34. LTSL attachment to AMB-1 
was not associated with loss of magnetic properties and viability; feature crucial for 
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targeted therapies (Figure3). These data are in line with prior research by Taherkhani et al 
43. When heat was added to AMB-LTSL therapy, a significant reduction in the viability 
of colon cancer cells (C26) relative to untreated control was noted in vitro (Figure 2h.). 
We believe that hyperthermia induced dox release from LTSL and sensitized colon 
cancer cells to doxorubicin therapy36,44. Interestingly, AMB-1 alone also induced 
cytotoxicity at body temperatures. Most likely, the AMB-1 byproducts triggered such 
effects12.  
Previously, conventional magnets/electromagnets have been utilized for peri-tumoral 
delivery of the magnetic bacteria45. As the conventional magnets or electromagnets 
magnetic field decays with an increase in depth, achieving the homogeneous distribution 
of the therapeutic agents in the tumor remains a challenge46,47. To overcome such 
barriers, we innovated by developing the Halbach array. AMB-1 CFU counts revealed a 
higher population in the focused tumors than the unfocused tumors (Figure4e). 
Additionally, a ~50 and ~5 log reduction in AMB-1 number in the spleen and liver 
compared to controls was observed when AMB-1 were magnetically attracted to the 
tumors with Halbach array (Figure 4f, g). However, the increase in AMB-1 population 
upon Halbach focusing didn’t accompany an enhanced dox fluorescence, iron-staining or 
MRI-contrast in focused vs unfocused tumors (Figure4, 5, 6). Future studies with a larger 
cohort of mice subjects and dosing regimens are needed to further uncover the 
localization mechanisms. In conclusion, our initial data suggest that AMB-LTSL 
demonstrates magnetic sensitivity and enhanced therapeutic effects in vitro.  
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Figure 1: a) Schematic of binding sites of streptavidin and biotin and complex 
formation; (b) Schematic for the attachment of AMB-1 to LTSL with streptavidin-biotin 
crosslinking chemistry. 
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Figure 2: In vitro characterization of AMB-LTSL. a) Dynamic light scattering showed 
a 2-fold increase in AMB-LTSL size relative to AMB-1; (b-c) FACS density plots and (d) 
Histogram obtained from AMB-LTSL showed enhanced doxorubicin fluorescence 
compared to AMB-1, indicating presence of fluorescent LTSLs on AMB membrane; (e)  
>90% of AMB-1 showed the presence of Dox fluorescence with streptavidin-biotin 
compared to those that were co-incubated passively with AMB-1; (f) Spectrophotometry 
showed a 3-3.5 fold enhanced Dox loading with streptavidin-biotin crosslinking 
compared to AMBs-co-incubated with LTSLs; (g)  Fluorescence microscopy of AMB-
LTSL showed red fluorescence indicative of LTSL attachment on the AMB-1. In contrast, 
unlabeled AMB-1control didn’t demonstrate dox fluorescence; (h) Dox, LTSL, AMB-1, 
and AMB-LTSL enhanced C26 killing at 42°C compared to 37 °C. Data normalized to 
control samples at 37°C. Values represent mean± SE (n=5) 
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Figure 3: Localization of AMBs with Halbach array and viability of  AMB-LTSL:  
(a) An array-based magnetic arrangement with a hollow center was used to test the 
localization of AMB-LTSL in 15mL tubes. AMB-LTSLs accumulated in the topmost 
layer of the falcon tubes with strong magnetic fields; (b) The viability of AMB-LTSL was 
not impacted with LTSL attachment compared to AMB-1 alone at 2,4,and 6h by sytox 
staining. 
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 Figure 4: AMB-LTSL targeting of colon tumor with Halbach array. a) Female 
Balb/c mice with tumor volumes of >400mm
3
 mice and injected intravenous (IV) with 
AMB-1 or AMB-LTSL were placed in the Halbach platform for 1 h; the (b, c, d) Tumor 
histology 2h post-treatment showed the presence of iron (blue color) in the AMB-1 and 
AMB-LTSL treated tumors in the presence and absence of Halbach focusing; (e-g) AMB-
1 Colony forming unit (CFU) per gram of tumor for AMB-1 was higher in Halbach than 
un-focused tumors. Conversely, liver and spleen tissues showed reduced AMB 
populations compared to unfocused mice groups (n=3), Values represent means ± SE for 
each treatment *p < 0.05 from control (t-test). 
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Figure 5: Fluorescence imaging of tumor sections. Whole-section fluorescence images 
scans acquired for untreated control and AMB-LTSL± Halbach focusing using a 10X 
objective didn’t show a significant difference in the doxorubicin fluorescence between 
various groups.  
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Figure 6:  MRI contrast of AMB-1 demonstrated a CFU dependent contrast enhancement 
in vitro; (b) T1-weighted MR images of tumors following IV delivery of AMB-1 ± 
Halbach focusing didn’t demonstrate an appreciable enhancement of AMB contrast in 
tumors. 
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CHAPTER V 
 
 
DISSERTATION SUMMARY AND CONCLUSIONS 
 
Colon cancer is typically treated with surgery, radiation, and chemotherapy, however, the 
5-year survival rates is yet to improve drastically (<15%)1. Newer approaches (e.g. 
immunotherapy) are starting to emerge, but attaining favorable outcomes in advanced 
stage metastatic disease remains challenging2.  To overcome these barriers, in this 
doctoral work, we specifically focused on enhancing chemotherapy outcomes by 
developing novel colon tumor-targeted low temperature sensitive liposomes (LTSLs)3. 
We modified the LTSLs to create image-guided and bacteria-mediated formulations such 
that they allowed real-time drug delivery and biodistribution estimations in colon tumors. 
Additionally, the interplay between chemo and immune-responses of colon tumors were 
assessed. In order to achieve the research objectives, we tailored LTSLs to achieve heat-
sensitive doxorubicin release, co-loaded with an ultrasound contrast agent, and attached 
to a bacterial membrane for targeted tumor delivery. The key findings of the doctoral 
research are described herein 
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Study 1: Chapter II 
The goal of this study was to develop ultrasound (US) imageable echogenic low-
temperature sensitive liposomes (E-LTSL) for contrast-enhanced reporting of tumor 
temperatures and doxorubicin delivery in mouse colon tumors. To do so, we first 
developed novel approaches to attain US images by compensating for tumor motion in 
real-time. For contrast imaging, E-LTSL was loaded with perfluoropentane (PFP) for 
active US imaging. We found that loading PFP into E-LTSL dramatically altered the 
phase-transition temperature from 29⁰C to ~40⁰C. We leveraged this property of E-LTSL 
to gain an understanding of tumor temperatures. We found that the vascular contrast of E-
LTSL as a function of temperature was strongly co-related, and this enabled a more 
robust estimation of temporal variations in colon tumor temperatures for 15-20 
min. Consequently, a marked increase in peak intensity at 42°C compared to 37°C that 
corresponded with transition temperatures of LTSL (~40⁰C), and enhanced doxorubicin 
delivery from E-LTSL in tumors was observed. Thus, our murine colon cancer work 
from this study suggest that E-LTSL monitoring of drug delivery and temperatures within 
tumors with US imaging feedback has the potential to significantly improve 
spatiotemporal reporting of colon cancer therap. 
Study 2: Chapter III 
The objective of this study was to attach LTSLs to Salmonella membrane (thermobot). 
For thermobot synthesis, Salmonella typhimurium (YS1646), a bacterialstrain with 
high chemotaxis towards the serine, ribose, and aspartate of benign and metastatic 
tumors was selected. We hypothesized that lipopolysaccharide (LPS), a classical 
activator of M1 macrophagespresent in the Salmonella typhimurium (YS1646) 
membrane will help overcome the doxorubicin resistance and immunosuppressive 
tumor microenvironment within the tumor microenvironment to directly improve 
LTSL colon cancer therapy. We optimized thermobot design principles; understand 
chemo-immunomodulatory mechanisms and therapeutic efficacy with and without 
colon tumor heating. We found that an average of 15–20 LTSLs attached to 
the Salmonella membrane, and actively attaching LTSLs using Biotin-Streptavidin 
chemistry significantly enhanced the loading of Dox without impacting bacterial 
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viability. Thermobot demonstrated efficient intracellular trafficking and cytotoxicity 
against colon cancer cell in vitro, and the cytotoxic effects were enhanced upon adding 
heat (~42⁰C). The efficacy of thermobot following tumor heating was superior in 
suppressing tumor growth rates compared to Salmonella or thermobot alone. This was 
likely due to triggered doxorubicin release in colon cells. Additional characterization 
of the treated tumors suggested an alteration of tumor immune environments with the 
highest increase in the expression of M1 macrophages when expressed as per gram of 
tumor for thermobot compared to all other treatments.  Additionaly, compared to 
untreated control, both Salmonella and thermobot infection of colon cells achieved a 
~2–3 fold increase in the helper (CD3+, CD4+) cells and interferon gamma (IFN-γ) 
expressing CD4+/CD8+ cells per gram of tumor plus and minus heating. Thus, we 
found that thermobot can be a novel agent for chemoimmunotherapy of colon cancer  
with tumor heating. Mechanistically, we learned that the thermobots work by enriching 
M1 macrophage phenotype and triggering the doxorubicin release in tumors to 
enhance therapeutic effects against colon cancer. 
 
Study 3: Chapter IV 
The aim of this study was to attach LTSLs on to Magnetospirillum magneticum (AMB-1) 
membrane for magnetic-guided localization of doxorubicin in colon cancer4. AMB-1 are 
flagellated, gram-negative, magnetic, aquatic bacteria containing magnetite (Fe3O4) 
particles. AMB-1 membrane surface also contains amines that can be leveraged for 
covalently attaching therapeutics on their surface. We hypothesized that if LTSL is 
attached to AMB-1, we would be able to guide them to the targeted area using an external 
magnetic navigation system such as Halbach array. Halbach array is a special 
arrangement of permanent magnets that augments the magnetic field on one side of the 
array while canceling the field to near zero on the other side. Results showed that LTSL 
attachment to AMB-1 with streptavidin-biotin chemistry did not cause a significant loss 
in bacterial viability. Adding heat to AMB-LTSL reduced the C26 colon cancer cell 
viability by ~ 70% at 42°C compared to AMB-1 alone. To assess AMB-1 targeting of 
colon tumors, mice were injected with AMB-1 and AMB-LTSL and the tumor bearing 
regions were placed on the Halbach array platform for 1h. This method of focusing 
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achieved a 5-log increase in AMB-1 population within the tumor compared to mice that 
were not placed on Halbach array. The population of AMB-1 was evident in the tumor 
sections and was mainly detected along the connective tissue septa or in perivascular 
locations of tumors. MRI imaging performed to correlate the bacterial population and 
histopathological finding did not demonstrate contrast enhancement. Most likely, the time 
between animal euthanasia and MRI imaging resulted in a reduction in MRI contrast to 
an undetectable level. These mechanisms will need to be further probed in the future. In 
conclusion, we successfully developed AMB-LTSL that demonstrates magnetic 
sensitivity and enhanced therapeutic effects in vitro; however, additional animal studies 
are required to bridge the translational gap. 
Future Perspectives 
This dissertation showed that LTSLs modified with therapeutic, imaging and navigations 
system can improve therapeutic outcomes in murine colon cancers. Our data is insightful 
in laying down a strong foundation for future studies focused on immune-modulations 
and longitudinal characterization of survival effects in preclinical and clinical patients. 
Specifically, how LTSL/bacterial agents impact the polarization of tumor macrophages, 
and enhance T-cell memory can provide important translational basis for systemic anti-
tumor immunity trials in colon cancer patients. Our multifunctional liposomes can also be 
extended to immune checkpoints inhibitor regimens for improved outcomes. We found 
that magnetic targeting of LTSL to tumors is limited by the strength of magnetic field. 
Thus, stronger magnets that localize magnetic nanoparticles at unlimited distance from 
the body surface are needed.  This will require innovations in the designing of novel 
Halbach arrays, and characterization of focusing with Alternating Magnetic Field (AMF) 
heating for improved outcomes. 
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APPENDIX A 
 
Abbreviations 
 
AMB-1 Magnetospirillim magneticum 
AMB-LTSL Magnetospirillim magneticum covalently bonded to low temperature 
sensitive liposomes  
AMF Alternating Magnetic Field 
APC antigen presenting cells 
BCG Bacillus Calmette-Guerin 
CD Cluster of differentiation 
CFU Colony forming units 
CRC Colorectal cancer  
CTLA-4 Cytotoxic T-Lymphocyte Associated protein 4 
Dox Doxorubicin 
DPPC 1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
DSPE-PEG-2000 1, 2-distearoyl-sn-glycero-3-phosphoethanolamine-N- [amino 
(polyethylene glycol)-2000] 
ELISA Enzyme linked immunosorbent assay 
E-LTSL Echogenic low temperature sensitive liposomes  
E-NTSL Echogenic non temperature sensitive liposomes  
EPR Enhanced permeability and retention effect 
GM-CSF Granulocyte-macrophage colony stimulating factor 
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HIFU High Intensity Focused Ultrasound 
HPLC High performance liquid chromatography 
Hsf Heat shock factors 
HSP Heat shock proteins  
IFN-γ Interferon-γ 
LPS Lipopolysaccharide 
LTSL Low temperature sensitive liposomes  
MDSC Myeloid-derived suppressor cells 
MHC Major histocompatibility complex 
MICA MHC class I polypeptide-related sequence A 
MRI Magnetic resonance imaging 
MSPC Myristoylstearoyl phosphatidylcholine 
NK cells  Natural Killer cells  
NMIBC Non-muscle invasive bladder cancer 
NTSL Non temperature sensitive liposomes  
PAMP pathogen-associated molecular patterns 
PD-1 Programmed Death -1 
PEG Polyethylene glycol 
PFP Perfluoropentane 
qRT-PCR Quantitative Real-Time Polymerase Chain Reaction 
RES Reticuloendothelial system 
RT-PCR Reverse Transcription Polymerase Chain 
SEM Scanning electron microscopy 
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TB Thermobot 
TB1 Salmonella typhimurium co-incubated with low temperature 
sensitive liposomes  
TB2 Salmonella typhimurium covalently bonded to low temperature 
sensitive liposomes  
TEM Transmission electron microscopy 
Thermobot Salmonella typhimurium covalently bonded to low temperature 
sensitive liposomes  
TLR Toll-like Receptors 
TNF-α Tumor necrosis factor alpha 
Treg Regulatory T cells 
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